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 Unresectable hepatic metastases of colon cancer poorly respond to 
existing therapies and are a major cause of colon cancer lethality. Transcription-
regulating Mediator kinase CDK8, an early clinical stage drug target, is amplified or 
overexpressed in many colon cancers and CDK8 expression correlates with shorter 
patient survival. Here we show that CDK8 inhibition does not generally suppress 
proliferation of CDK8-overexpressing colon cancer cells but nevertheless CDK8 
knockdown by shRNA or CDK8 kinase inhibition by a selective small-molecule drug 
candidate suppresses metastatic growth of mouse and human colon cancer cells in the 
liver. This effect is due at least in part to the inhibition of already established hepatic 
metastases, indicating therapeutic potential of CDK8 inhibitors in the metastatic setting. 
In contrast, CDK8 knockdown or inhibition has no significant effect on the growth of 
tumors implanted subcutaneously, intrasplenically or orthotopically in the cecum. 
Mechanistically, the site-specific effect of CDK8 on colon cancer growth in the liver is 
mediated through the downregulation of matrix metalloproteinase (MMP) inhibitor 
TIMP3 via the TGFβ/SMAD-driven expression of a TIMP3-targeting microRNA, miR-181b, 
along with the induction of MMP3 in murine or MMP9 in human colon cancer cells via 
Wnt/β-catenin-driven transcription. These findings reveal a new mechanism for negative 
regulation of gene expression by CDK8 and a site-specific role for CDK8 in colon cancer
vi 
 
hepatic metastasis. Our results indicate potential utility of CDK8 inhibitors for the 
treatment of colon cancers that metastasized into the liver and suggest that CDK8 
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CHAPTER 1 GENERAL INTRODUCTION 
Colorectal cancer and animal models  
Colorectal cancer (CRC) refers to the cancer that develops from the large intestine 
(colon) or the rectum, which, depending on the cause of its occurrence, can fall into two 
groups, sporadic colon cancer and colitis-associated cancer1. Sporadic CRC usually starts 
as a polyp, which is an abnormal growth on the inner surface of the colon or rectum and 
with the mutation of Adenomatous polyposis coli (APC). However, in most cases polyps 
are benign and the potential to become CRC depends on the polyp types, grade of 
dysplasia, location and the tissue environment2.  With the accumulation of mutations, 
such as mutations of K-ras and p53, polyps will develop into carcinoma3. In the case of 
sporadic CRC, the mutations are mainly due to chromosomal instability, microsatellite 
instability and loss of function of the tumor suppressor genes such as APC. In the case of 
colitis associated CRC, chronic inflammation induces oxidative stress, aberrant 
inflammatory and tissue repair signaling, which further causes the activation of Wnt/β-
catenin pathway and initiation of dysplasia4. Dysplasia will eventually progress to 
carcinoma with sustained chronic inflammation1.  In fact, inflammation, together with 
other factors, can also promote CRC metastasis, where CRC cells invade though the 
intestinal wall and spread into distant organs via blood and/or lymph system5.  
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According to the Facts & Figures 2017-2019, CRC is the third most common 
carcinoma worldwide, with estimated 95,000 newly diagnosed cases and 50,000 deaths 
in the US in 2017. The current survival rate for CRC is 65% at 5 years and 58% at 10 years. 
For the patients with localized stage CRC, the 5-year survival rate is 90%, however, for 
the patients diagnosed with distant metastases, survival rates decline to 14%, which 
accounts for about 24% of all CRC patients6,7. Liver is the most common organ of CRC 
metastasis and CRC metastasis can also happen in the lungs, bones, peritoneum and 
brain. For the patients with CRC metastasis, only 15-20% are suitable for surgery8. 
However, the primary goal of surgery resection for CRC patient with metastasis is to 
remove the local colon tumor and prevent other local complications. If there are only a 
few metastases in the liver or lungs, surgical removal can improve survival. But in most 
cases, metastatic tumors are usually scattered in organs at different sites and most of 
them are beyond the detection capacity, and therefore are hard to be removed by 
surgery. Even worse, surgery has been shown to induce metastatic colorectal cancer 
tumor growth9.  Nowadays, the first-line chemotherapies for CRC at different stages, 
including metastatic disease, are 5-fluorouracil supplemented with folinic acid and 
oxaliplatin or irinotecan (FOLFOX or FOLFIRI, respectively)10,11. Although they provide a 
marginal survival advantage in metastatic colorectal cancer12, these chemotherapies 
usually bring serious side effects due to the indiscriminate killing of proliferating cells 
which limits the utility of these regimens. Several targeted therapies have been approved 
in recent years by FDA, such as regorafenib, targeting new blood vessel growth, and 
nivolumab in combination with ipilimumab, targeting the immune system13,14. New 
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therapeutic approaches and novel drugs for CRC, especially for CRC metastasis, are still in 
great demand. 
Animal models, especially mouse models, are of critical importance for anticancer 
drug development, shortening research period and providing information that can’t be 
obtained from humans directly. Due to the high reproductive efficiency and the 
availability of inbred strains to diminish genetic and physiological variations between 
individuals, mouse models are especially useful for drug efficacy testing15. However, only 
about 5% of the anticancer therapies, although effective on animal models and entering 
clinical trials, are approved by FDA for clinical use16, suggesting the mouse models may 
not reflect the human disease faithfully. Full understanding of the scope of application of 
different models is critical for proper experimental design. In this section, the current 
laboratory mouse models for CRC research will be discussed. 
Chemically induced CRC models 
 
Unlike the high incidence of spontaneous CRC in human beings, mice rarely 
develop CRC spontaneously, less than 1%17. High incidence of CRC in mice, necessary for 
routine experimental use, can be induced by exposure to carcinogens 16. Currently, the 
precursors of methylazoxymethanol (MAM), 1,2-Dimethylhydrazin (DMH) and the 
metabolite azoxymethane (AOM) are the two most commonly used carcinogens for CRC 
induction in mouse model. MAM, found in cycad seeds, can yield methyl diazonium ion, 
which can alkylate macromolecules in liver and colon and lead to tumor development18. 
Beta-catenin mutations, stabilizing beta-catenin, are very common in AOM induced colon 
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tumors in mouse19,20. AOM is more frequently used than DMH due to greater potency 
and increased stability21. AOM is usually administered repeatedly for 6-8 weeks via i.p. or 
s.c. injection to induce colonic malignancy in mice and the tumor burden is evaluated 
starting 30 weeks after the first injection of AOM. The mouse model induced by AOM 
administration is very useful for studies on carcinogenesis and chemoprevention, such as 
the role of diet-induced obesity on colon tumor development22 and evaluation of drugs 
for chemoprevention23.  AOM can be also administered with dextran sodium sulfate 
(DSS) solution orally, which provides the current colitis induced CRC mouse model. The 
combination of AOM and DSS induced colitis related CRC provides a useful model for 
chemoprevention of CRC by targeting bowel inflammation24.  
Genetically modified mouse models 
 
Despite the evolutionary distance, the contents of the mouse and human 
genomes are largely conserved25, and the signaling pathways involved in cancer are 
comparable in both species26. The backgrounds of inbred laboratory mouse strains have 
been well investigated providing valuable models for biology research at molecular level. 
Genetically modified mice cultured in a controlled environment provide very useful 
cancer etiology models.  
ApcMin/+ models 
Adenomatous polyposis coli (APC) gene is one of the key tumor suppressors in 
human colon and is conserved in mammals27. ApcMin/+ mice were first derived from 
ethylnitrosourea mutagenesis screen for C57BL/6 mice with multiple intestinal neoplasia 
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(Min)28. ApcMin/+ mice carry a nonsense mutation at codon 850 of the Apc gene and were 
recognized as a mouse model paralogizing human familial adenomatous polyposis (FAP) 
syndrome29. Apc gene was also found to be somatically altered in more than 80% 
sporadic CRCs30. The homozygous ApcMin/Min are embryonic lethal28. ApcMin/+ mice develop 
multiple neoplasias throughout the intestinal tract within several weeks after birth, and 
are considered to be a valuable model for tumorigenesis research31. However, in this 
model most of the tumors develop in the small intestine instead of colon32 and most of 
the mice die from anemia and cachexia at 120 days of age33.  Due to the short lifespan, 
none of the neoplasias progress to adenocarcinoma and metastasis in these mice34. 
Apc1638N/+ mice, with Apc chain-terminating mutation introduced into the germ line, 
could live longer and liver metastases were detected in those mice that lived for more 
than one year35. But since only a few mice could reach that age, this model is not good 
for investigation that needs large groups, such as drug testing.  
In order to generate more CRC models, further genetic mutations, especially 
those in genes involved in different stages of CRC development, have been introduced 
into Apc mutant mice. Through a great deal of cross breeding between different 
genetically modified mice, K-ras mutation was found to be necessary for adenoma 
formation and p53 inactivation was required for carcinoma formation36. Crossing of mice 
carrying mutations of Braf (V637E) or Kras (G12V) with mice with inactivation of a tumor 
suppressor gene, such as ink4a/Arf, p53 or Tgfbr II, with the ApcMin/+ background leads to 
metastasis in different organs depending on the specific gene modification37,38. However, 
none of these models are potent enough to produce metastasis with a high percentage 
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and short latency39. Research with these models generated a lot of key information about 
the driver genes for different stages of CRC development39. However, the tumors derived 
from genetically engineered mouse models (GEMMs) lack heterogeneity of genetic 
background, which is initiated and maintained by the same genetic mutation, which is in 
a striking contrast to the tumors from human being40.  The lack of heterogeneity of 
GEMM tumors limits their use to faithfully recapitulate human CRC for pre-clinical 
studies. This is especially common in drug efficacy research. Some drugs are effective in 
GEMMs with a simple and clear genetic background, however they fail in the clinical trials 
due to the heterogeneity of human tumors41. 
Tumor implantation models 
The implantation of tumors in mice has been widely used since the 
immunocompromised mice were discovered in 1960s. Implantation, especially 
subcutaneous implantation, is an easy operation and of relatively low cost and thus 
nowadays is widely used in the testing of novel therapeutics. Immortalized human CRC 
cell lines with different genetic background are commercially available for subcutaneous, 
orthotopic or intra-splenic implantation into immunocompromised mice, such as nude or 
severe combined immune deficiency (SCID) mice. However, the tumors of these models 
are derived from cell lines and lack heterogeneity as do the GEMM models. Patient 
derived xenografts (PDX), samples derived directly from patient without selection, are 
used to recapitulate heterogeneity in tumor, including not only the complexity of gene 
mutations but also the microenvironment around tumor cells. The genetic and 
microenvironment heterogeneity in PDX models can be kept for several passages but will 
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be lost eventually. PDX also requires access to human CRC tissue, which is not easily 
available for most research labs. There are also immortalized mouse CRC cell lines 
available, most of them generated by chemical induction, for syngeneic implantation in 
immunocompetent mice for preclinical research, which is especially important for those 
drugs that are involved in immune system modulation.  
Subcutaneous implantation  
Nowadays the most widely used CRC models are based on the subcutaneous 
implantation with inoculation of a suspension of tumor cells in PBS or growth medium 
without serum into the flank(s) of immunocompromised mice. Almost all the 
commercially available human CRC cell lines are suitable for this model. The tumors in 
the subcutaneous model are usually palpable in one week for CRC model and the tumor 
volumes are conveniently obtained by measuring with caliper. At the end of experiment, 
the subcutaneous tumors can be easily and rapidly removed and snap frozen for 
subsequent RNA and protein analysis. However, the disadvantage of this type of model is 
also obvious. The major and marked disadvantage is the microenvironment in 
subcutaneous implantation, which is clearly different from that in human CRC tumor. The 
interaction between tumor cells and stromal cells determines the gene expression 
profile, metastatic behavior and overall and disease free survival of patients42. In the 
subcutaneous implantation tumor model with tumor cell lines, stroma is seldom found. In 
fact, the ratio of tumor cells and stroma stands as a robust independent prognostic factor 
in colon cancer42. There are also no liver metastases reported in CRC subcutaneous 




Orthotopic implantation of CRC cancer in mouse models refers to the injection of 
a suspension of tumor cells or a piece of tumor fragment from a mouse model or from a 
patient directly into the caecum, colon or rectum of mouse. Since tumor growth in 
caecum is less life-threatening than tumor growth in colon or rectum and caecum is 
conveniently exteriorized, caecum is the most common site for CRC orthotopic 
implantation. The wall of caecum or colon of mice is too thin for naked eye operation and 
the implantation of tumor cells should be conducted under a stereo zoom microscope. A 
suspension of tumor cells can be injected into the caecum wall and sealed with glue in 
case of leakage. The fragment of tumor from other mice or a human patient can be 
implanted under serosa membrane of caecum. Besides exposure of the abdominal cavity, 
injection of tumor cells into rectum through anus has been tried, but tumor take rate was 
relatively low and tumor burden in rectum posed problems with defecation which limited 
the tumor size43. Compared to the subcutaneous model, orthotopic implantation mimics 
the microenvironment of CRC tumor much better, since the tumor directly grows in the 
colon-like environment. Tumor invasion and metastasis to distal organs, such as liver, 
have been observed very commonly in this kind of models44. The metastasis rates in the 
liver depend on the cell line and mouse strain. Intra-mural orthotopic implantation of 
MCA-38 cells into C57BL/6 mice resulted in about 70% spontaneous liver metastasis after 
8 weeks inoculation45. For CT26 mouse colon cancer cells, subserosal orthotopic 
implantation in Balb/cByJ mice gave 100% primary colonic tumors, but only 8% 
spontaneous liver metastases after 8 weeks of tumor growth. However, CT26-FL3 cells, 
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generated through 3 rounds of liver metastasis selection, gave 90% spontaneous liver 
metastases in the same model46. For human CRC cell lines, such as HCT116 (one of 12 
tested CRC cell lines), primary tumor take rates in orthotopic implantation into BALB/c 
nude mice for 6-8 weeks was 100% and about 70% of mice were found with lymph node 
metastases, however, no spontaneous liver metastases were found in this model47. In 
contract to the latter study, HCT116 cells orthotopic injection into Swiss Nu/Nu mice 
resulted in about 70% spontaneous liver metastases after 8 weeks inoculation48, 
suggesting the importance of host environment during the process of tumor metastasis.  
Compared to the subcutaneous model, the most important advantage of 
orthotopic implantation is that it’s capable of mimicking the microenvironment of CRC, 
which plays key roles in the growth and proliferation of cancer cells at the primary site49. 
However, the limitation of this model is obvious. It is time and energy consuming to do 
cell injection in abdominal cavity and meanwhile the growth of tumors adds burden to 
the intestinal system, which could lead to mortality of experimental mice. The leakage of 
tumor cells during operation can result in scattered and random tumors in abdominal 
cavity including liver (arising not through the blood system but though leakage from the 
injection site).  
The metastasis mouse models 
Due to the early detection of benign colonic adenomas, the mortality of colorectal 
cancer decreased during the last 50 years50. However, treatments of metastatic CRC 
metastasis are still relatively ineffective. Since the majority of CRC related deaths are 
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caused by metastasis, it is extremely important to elucidate the mechanisms behind 
tumor invasion and metastasis. The metastasis of tumor cells from the primary site to 
remote site usually includes several successive steps: a) local invasion and intravasation, 
b) dissemination through the circulation system, c) extravasation at the metastatic site, 
d) colonization at the metastatic site51. The ideal model of metastasis should recapitulate 
all the steps and mimic the mechanisms behind these processes, such as gene alterations 
required for invasion and metabolism adaption for cell survival in circulation system and 
so on. A good model also should be predictable and reproducible and be available to 
validate novel therapeutics. However, there is no model that can meet all the 
requirements. Models should be selected according to the experimental purposes. For 
the drug development targeting CRC metastasis therapy, i.e. the metastatic tumors that 
have already been established in the patients, models that mimic step d), colonization at 
the metastatic site, should be the most suitable.  
The most widely used models for CRC liver metastasis research are injection of 
tumor cells into the spleen or portal vein of mice. The injected cells reach hepatic 
microcirculation through hepatic portal vein and will be arrested by cell size or specific 
adhesion between cells from hepatic microenvironment and newly arrived tumor cells52. 
Some of the arrested cells undergo extravasation and finally form colonies in the liver, 
while most of the injected cells will die and disappear. High rates of metastases usually 
can be achieved in this model. Syngeneic injection of 0.1 million CT26 cells into spleens of 
BALB/c mice resulted in 100% liver metastases in two weeks. Similarly, syngeneic splenic-
injection with MCA38 cells in C57BL/6 mice also developed hepatic metastases with 
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100% occurrence53. The high rates of metastases were also observed in the xenograft 
splenic injection of human colon cell lines in the immunocompromised mice. Splenic 
injection of HCT116 at different cell numbers demonstrated 100% liver metastasis 
establishment at 25 days after injection54. Splenectomy can be applied to eliminate the 
effect of tumors in spleen and let the metastatic tumors fully develop in the liver, 
especially for the survival studies55.  
The splenic injection model provides several advantages for metastasis research. 
As discussed above, this model can give about 100% metastasis formation, making it very 
suitable for novel drug testing. Also this model is applicable for CRC hepatic metastasis 
disease specific survival study since liver is the only metastatic organ. However, the 
disadvantages of this model are also evident. It only mimics the last two steps of 
metastasis, extravasation and colonization in liver. The dissemination steps of the process 
of metastasis are missed. Surgery in this model requires well-trained person and is time 
consuming. Since the metastatic tumors grow in the liver inside the cavity, it is very hard 
to trace the growth of metastatic tumors. The tumor cells can be labeled with 
fluorescence or bioluminescence by stable transfection or virus mediated transduction 
and the signal can then be acquired by an in vivo imaging system, however, unlike the 
subcutaneous model, the signal of fluorescence or bioluminescence is easily influenced 
by the location of signal emitting cells.  
Besides intrasplenic injection model, direct injection of colon cancer cells via 
hepatic portal vein or in liver parenchyma has also been used to mimic clinically relevant 
colon cancer hepatic metastasis56,57. Compared to splenic injection model, however, 
12 
 
portal vein injection usually results in rapid cell death of the injected colon cancer cells 
and forms relatively less metastasis58. In the splenic injection model, the injected tumor 
cells are accompanied by splenocytes, in a similar manner as bone marrow cells, which 
protect tumor cells from stress-induced cell death58.  Direct injection of colon cancer cells 
into liver parenchyma also puts no metastatic selection pressures, such as the shear force 
from blood stream, on the injected cells, which makes this model less clinically relevant59.  
Summary 
All the mouse models for colorectal cancer have contributed to our 
understanding of the progression of human CRC, from carcinogenesis to remote 
metastasis. Different models are applied for different kinds of research. The best 
approximation of human cancer is achieved with the PDX model, which contains all the 
tumor flora and extracellular matrix directly from human patients.  However, due to the 
immunological differences between two species, there are still great limitations for the 
mouse models with patient derived samples, which are believed to best recapitulate 
human CRC growth. That problem has been greatly relieved by the mice with humanized 
immune system that are now available for PDX models, which may provide superb tools 
for immunotherapy investigations60. Tumor implantation models remain the mainstay of 
CRC drug testing and splenic injection offers the most reliable approach to testing new 
therapies in a metastatic setting. 
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Background of CDK8 
Cyclin dependent kinases (CDKs) are a family of serine/threonine kinases whose 
kinase activity is dependent on the binding of cyclin family proteins.  At least 20 
mammalian CDKs have been predicted and identified61,62 and can be roughly divided into 
two broad categories: cell cycle related, such as CDK2, CDK4, CDK6; and transcription 
regulation related, such as CDK7, CDK8, CDK962,63, although these two groups may 
overlap in specific contexts64. CDK8 was originally identified in human cells as a potential 
kinase partner of cyclin C (CycC)65. By physically binding CDK8, cyclin C protein can be 
protected from degradation66,67.  CDK8 was subsequently found to function, as both a 
positive and a negative regulator of transcription in different contexts through different 
mechanisms68.  CDK8, together with its closely related paralog CDK19, further distinguish 
themselves by being the only kinases in the Mediator complex69. The Mediator complex, 
also called Mediator co-activator complex, is a multi-protein complex which functions as 
a “bridge” connecting RNA polymerase II and transcription factors and sometimes 
enhancer-binding factors, and thus bends the chromatin forming transcription 
preinitiation complex70-72. CDK8 or CDK19, cyclin C, MED12 or MED12L and MED13 or 
MED13L form CDK8/19 subcomplex module (CKM)73. CKM could be either in free status74 
or associated with core Mediator (the Mediator complex without CKM) mediated by 
MED1375 (Fig. 1.1). The components of CKM function differently in transcription 
regulation76 and biological development77. Unlike most of the kinases, the roles played by 
CDK8/19 can be kinase independent78,79. As a pair of paralogs, CDK8 and CDK19 are 
interchangeable under specific biological conditions80, however, in most instances, 
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dysregulation of CDK8 or CDK19 causes distinct biological consequences, especially in 
disease development. In this review, we provide an overview of our understanding of the 
regulation of CDK8/19 expression, the roles of CDK8/19 in RNA transcription and disease 
development, especially in cancers.  
 
 
FIGURE 1.1 The Mediator kinase module and Mediator complex in gene transcription. 
The Mediator kinase module and Mediator complex in gene transcription: CDK8, 
CycC, MED12 and MED13 compose Mediator kinase module. The core Mediator complex 
consists of roughly 26 subunits and it can be divided physically into three parts, head, 
middle and tail. The Mediator kinase module and core Mediator complex are joined into 
the whole Mediator complex by Med13. The tail part and middle part of the Mediator 
complex can bind to transcription factors which may be subject to CDK8 kinase 
phosphorylation. The tail part of Mediator complex can bind to the factors that recognize 
enhancer elements and stabilize promoter/enhancer loops. CDk8 kinase module can also 
be free from Mediator complex285.   
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Regulation of CDK8 expression 
CDK8 is constitutively expressed in most types of cells and tissues, to some degree 
like house-keeping genes. Compared to its extensively studied functions, the regulation 
of CDK8 expression is less investigated, however, we will still review the regulation of 
expression of CDK8 at the stages of mRNA synthesis, stability, alternative splicing and 
protein stability (Fig. 1.2).  
mH2A1 
MacroH2A (mH2A) is an isoform of H2A histone variants, with a 30 Kd non-
histone domain (macro domain) at the C-terminus; it is generally considered to be 
transcriptionally repressive81. CDK8 expression is reversely regulated by mH2A1 at the 
transcriptional level. A global decrease of the expression of histone variant macroH2A, 
mH2A1 and mH2A2, was observed in highly malignant melanoma cells, those with 
increasing metastasis potential, and in the metastatic sites compared to primary 
melanoma82. Gene expression profiling demonstrated that the expression of CDK8 
increased dramatically in the cells with mH2A1 or mH2A2 stable knockdown; in the highly 
malignant melanoma cells mH2A was found enriched at the CDK8 promoter by chromatin 
immunoprecipitation (ChIP) analysis; by quantitative PCR (qPCR) and 
immunohistochemistry (IHC) analysis of fresh melanoma specimens, the expression of 
CDK8 and mH2A were significantly inverse correlated82. Knockdown of CDK8 could largely 
reverse melanoma cell proliferative advantage induced by mH2A loss82. The 
downregulation of CDK8 expression by mH2A vanished in highly malignant tumors 
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implying a role for CDK8 in melanoma metastasis. Similar phenomena were also observed 
in breast cancer, with CDK8 expression upregulated while mH2A1 downregulated with 
increasing breast cancer grade, and the expression of CDK8 and mH2A1 was significantly 
inversely correlated83.  All these data together suggest that CDK8 expression is repressed 
by mH2A, directly or indirectly.  
miRNAs 
MicroRNAs (miRNAs) are a family of small noncoding RNAs containing about 22 
nucleotides, which can bind to mRNA and negatively regulate their target genes84. The 
expression of miRNAs is commonly dysregulated in cancer85. By dual-luciferase reporter 
assay, CDK8 was identified as the target of miR-195-5p in colon cancer cells86. In breast 
cancer cell line MDA-MB-231, miR-107 directly targeted 3’UTR of CDK8 and negatively 
regulated CDK8 expression at mRNA and protein levels87. The same regulation was also 
found in gastric cancer cells88 and non-small cell lung cancer cells89, in which CDK8 could 
be inhibited by miR-107. Aside from miR-107, in breast cancer cells MDA-MB-231 and 
MCF-7, miR-26b directly targeted the 3'UTR of CDK8 downregulating both CDK8 and β-
catenin expression90.  Recently, miR-26a, a tumor suppressor miRNA91, was 
demonstrated to directly target CDK8 3’UTR and down-regulate its expression in 
hepatocellular carcinoma cells, and consequently decrease the expression of c-Myc 92. 
Interestingly, the relationship between miR-26a and CDK8/c-Myc shows negative 
feedback regulation, which suggests that high level of CDK8/c-Myc inhibits miR-26a 
expression while miR-26a targets and down-regulates CDK8/c-Myc92.  
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Besides miRNAs, long non-coding RNA (lncRNA) also play an important role in the 
regulation of CDK8 expression. H19, among other lncRNAs, was identified as the lncRNA 
that was most significantly associated with survival by regulating RB1-E2F1 and β-catenin 
activity, which have been shown to be regulated by CDK893,94. In fact, knockdown of H19 
resulted in CDK8 downregulation in several colon cancer cell lines95.  
Alternative splicing 
RNA transcribed from DNA has to undergo splicing to remove introns and connect 
exons and other processing to form mature mRNA. Alternative splicing results in different 
mRNAs and different proteins, and thus regulates the abundancy, activity and stability of 
target protein96.  Through the analysis of RNA-Seq data of endothelial progenitor cells 
followed by RT-PCR, cloning and Sanger sequencing, new transcript of CDK8 that lacks 
exons 5 and 7 was discovered. Protein prediction of the new transcript revealed that the 
new CDK8 isoform lacks proton and ATP binding residues as well as the entire cyclin C 
binding domain and most of the protein kinase domain97. Alternative splicing has been 
also observed for CDK19. Whole transcriptome sequencing of bone marrow biopsy 
specimens from castration-resistant prostate cancer (CRPC) found high intronic read 
death in CDK19 along with some other genes. Further analysis showed the majority of 
CDK19 transcripts were inefficiently spliced in CRPC specimens98.  
mTORC1 
The expression of CDK8 was decreased and inversely correlated with the activity 
of mTORC1 in the livers from human non-alcoholic fatty liver disease (NAFLD) and the 
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leptin receptor-deficient (db/db) and leptin-deficient (ob/ob) mice, the most widely used 
animal models for obesity with insulin resistance and fatty liver; inhibition of mTORC1 
activity by Rapamycin or Torin 1 or shRNA significantly repressed the nutrient-repletion 
induced CDK8 down-regulation both in vitro and in vivo; and also in contrast to increased 
mTORC1 activation in liver during aging, the expression of CDK8 declined as mice get 
old99. A recent paper showed that, in Drosophila cells, TORC1 induced CDK8 degradation 
by ubiquitin/proteasome which could be reversed by MG132 treatment100. 
 In addition to degradation of CDK8, MED13/13L is also subject to 
ubiquitin/proteasome system. Fbw7, the substrate recognition component of SCF (Skp–
Cullin–F-box) ubiquitin ligase, could bind to and promoted MED13/13L ubiquitylation and 
degradation, and consequently dismantled CDK8/19 subcomplex module and presumably 
changed its activity in transcription101.  
 
 
FIGURE 1.2 The regulation of CDK8 levels in cells. 
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The transcription of CDK8 can be repressed by mH2A; the mRNA level of CDK8 
can be regulated by alternative splicing of pre-mRNA and targeted by miRNAs. CDK8 
protein is also subject to proteasome degradation by mTORC1 mediated modification. 
The difference between CDK8 and CDK19 
CDK8 and CDK19 are evolutionary twins in the CDK family, and they diverged after 
the emergence of vertebrates102.  Compared with CDK8, CDK19 carries an extra 
Glutamine-rich domain and Arginine/Serine-rich domain. Glutamine-rich domain in 
eukaryotic transcriptional regulators acts as a functional modulator103,104 and is enriched 
in metabolic processes103, while the Arginine/Serine-rich domain is mainly involved in 
pre-mRNA splicing105,106. Despite 97% identity of amino acid sequence in the kinase 
domain, CDK8 and CDK19 are different in many ways, especially in their biological 
functions.  
According to the Cell Atlas107, CDK8 together with MED12, MED12L, MED13, 
MED13L localize exclusively in the nucleus, whereas CDK19 and cyclin C are found almost 
equally in cytoplasm and nucleus, implying that CDK19 might function to a large degree 
without Mediator complex (Fig.1.3 A). While CDK8 gene localizes to 13q12 region, CDK19 
and CCNC genes localize to 6q21 region very closely to each other. The gene location and 
cellular distribution suggests that CDK19 might interact even more closely with CycC than 
CDK8 does. RNA-seq data of 17 cancer types by The Cancer Genome Atlas (TCGA)108 
show that CDK8 is highly expressed in colorectal cancers while CDK19 was most abundant 
in prostate cancers.  Analysis of RNA expression in different human tissues by FANTOM5 
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Cap Analysis of Gene Expression project109 reveals the different expression patterns of 
CDK8 and CDK19, with high expression of CDK19 in brain and related tissues, such as 
caudate, cerebellum, hippocampus and pituitary gland (Fig. 1.3 B).. Consistently with 
these data, CDK19 was found disrupted in a female patient with congenital bilateral 
falciform retinal folds, and Drosophila CDK8, the orthologue of both CDK8 and CDK19, 
was a key regulator of dendritic development110. CDK8 and CDK19 are also not mutually 
replaceable during mouse embryo development, CDK19 could not compensate CDK8 
knockout induced embryo lethality111. 
 
FIGURE 1.3 The distribution of CDK8 and CDK19 in tissues and in cells. 
A. The information on Cyclin C, CDK19 and CDK8 distribution in cells is from CELL 
ATLAS, which summarizes the distribution of proteins in several cell lines using several 
antibodies. B. The expression of CDK19 and CDK8 in different human tissues obtained 
through Cap Analysis of Gene Expression (CAGE) is reported as Tags Per Million, 
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generated by the FANTOM5 project. The orange line represents the average value of 
gene expression from all tissues.  
The gene expression changes in derivatives with the stable knockdown of CDK8 or 
CDK19 were largely nonoverlapping in the routinely cultured HCT116 cells, or under the 
specific conditions such as  genotoxic stress stimuli and glucose deprivation112. However, 
one should keep in mind that multiple phenotypic changes may arise from clonal 
selection during the generation of stable knockdown cell lines. Also in HCT116 cells, CDK8 
specific inhibition by gene modification decreased GLUT3 expression, however dual CDK8 
and CDK19 inhibition induced GLUT3 expression significantly113.  Considering that GLUT3 
is the main glucose transporter in neurons114, induction  of GLUT3 expression by 
inhibition of CDK19 implies that CDK19 might play an important role in neuronal system 
metabolism. Putting all the data together, CDK19 has a significant role in neuronal 
system, which should be taken into consideration when developing drugs that target 
CDK8 and CDK19. 
The role of CDK8 in transcription 
Dysregulation of transcription has been observed in a variety of diseases115. 
Genome-wide location analysis by ChIP coupled with DNA microarray in yeast revealed 
that core Mediator complex was co-localized with Pol II at the promoters of both inactive 
and active genes, and CDK8 submodule largely overlapped with core Mediator by 
transient interaction116. However, rather than as a general transcriptional factor,CDK8 or 
CDK8 submodule functions as regulator of context specific gene expression, such as 
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during differentiation of budding yeast Saccharomyces cerevisiae 117, development of 
drosophila larvae77 and mouse embryo111, with complicated and dramatic gene 
expression changes in all these conditions. In routine cultured cells or the fully developed 
organisms, where the gene expression is supposed to be stable, depletion of CDK8 does 
not affect the cell or organism viability77,111,118. 
CDK8 is capable of modulating transcription via the Mediator complex, which 
plays fundamental roles in chromatin remodeling, preinitiation complex (PIC) and  pre-
elongation complex (PEC) formation71,119. CDK8, as well as CDK7 and CDK9, is able to 
phosphorylate the carboxy-terminal domain (CTD) at Ser2 and Ser5120-122, modification of 
which can facilitate or (as described in yeast studies) halt the transcriptional activity of 
Pol II123. CDK8 can also directly phosphorylate transcription factors to potentiate their 
transcriptional activity and/or alter their proneness to degradation (Fig. 1 4). We will 
describe the role of CDK8 in transcription regulation in greater detail below. 
Negative regulation 
The initial research that investigated the role of CDK8 in transcription was in 
yeast; Srb10, the yeast homolog of CDK8 was believed to generally repress transcription 
in vivo124.  Transcription and electron microscopy studies demonstrated that CDK8 
subcomplex physically competed with Pol II binding to Mediator complex and thus 
inhibited the necessary interaction between Mediator complex and Pol II within the 
Preinitiation Complex78,125,126. However, the transcription inhibition by CDK8/19 
subcomplex is kinase independent in human cells125.  Mediator complex with or without 
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CKM module purified from Hela nuclear extract showed different activities in Pol II 
mediated transcription. The Mediator complex without CKM module exhibited higher 
activity in enhancing transcription initiation and reinitiation, which was necessary for 
continuous transcription127. In the HIV provirus infected Jurkat cells, the HIV promoter in 
the viral long terminal repeat (LTR) was occupied by CDK8 module and transcriptionally 
silent in the latent status; upon stimulation with TNF-α, CDK8 occupation disappeared in 
the LTR promoter region and higher transcription of HIV related genes was observed 
consequently128. Interestingly, in contrary to CDK8 protein itself, the kinase activity of 
CDK8 was necessary for HIV-1-LTR-driven gene expression129, suggesting the kinase 
dependent and kinase independent roles of CDK8 might totally deferent under certain 
biological contexts. In addition to direct regulation of transcription, CDK8 can repress 
cdk7 kinase activity by phosphorylation of cyclin H at Ser5 and Ser304, the kinase 
subunits of the transcription factor II human (TFIIH) module130-132, which is necessary for 
the release of Pol II from PIC to the pausing status133 (Fig.1.4 A).  
Positive regulation 
In addition to repressing transcription, CDK8 is capable of positively regulating 
transcription. Yeast two-hybrid screening revealed that some transcriptional cofactors 
bound to CDK8/CDK19 submodule directly134. In Hela cells, CDK8 interacted with viral 
transactivators E1A and VP16 and functioned as a positive regulator in transcription135;  
knockdown of CDK8 by siRNA repressed the transcription of exogenous Gal4-VP16 driven 
luciferase136. CDK8 could also collaborate with TRRAP/GCN5L, an acetyltransferase, to 
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result in tandem histone 3 phosphorylation/acetylation, which was correlated with 
transcriptional activation, in the reconstituted human cell system and in HCT116 cells137.  
CDK8 can also positively regulate transcriptional activity by directly modifying the 
stability of Mediator complex components. CDK8 but not kinase dead mutant CDK8 has 
been shown to interact with and phosphorylate Med3, a potent activator of transcription 
in Mediator complex; phosphorylation of Med3 at S191 residue led to its interaction with 
Grr1, a E3 ligase, and finally ubiquitination and degradation in yeast138 (Fig.1.4 B).  
 
 
FIGURE 1.4 CDK8 regulates transcription. 
A. CDK8 is capable of repressing Pol II mediated transcription by physically 
preventing Pol II binding to Mediator complex and by disabling CDK7 by phosphorylation 
of CycH, which primes CycH degradation. B. CDK8 can also promote Pol II mediated 
transcription by stabilizing Mediator complex components (Med3), recruiting histone 
acetyltransferase (GCN5) and transcription factors, which can be subject to CDK8 
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mediated phosphorylation. CDK8 can also phosphorylate the C-terminal domain (CTD) of 
Pol II directly. 
CDK8 seems to exert a significant effect on the expression of super-enhancer 
related genes. By using chromatin immunoprecipitation followed by sequencing (ChIP-
seq), CDK8/19, together with Mediator complex and other transcription factors, CDK8 
was found to be highly concentrated at super-enhancers in acute myeloid leukaemia 
(AML) cells139. Inhibition of CDK8/19 with cortistatin A (CA), significantly induced the 
expression of super-enhancer associated genes; and this was confirmed by W105M point 
mutation of CDK8/19, conferring resistance to CA, in which the gene induction effect of 
the inhibition of CDK8 by CA was largely abolished139.  
The role of CDK8 in regulating the activity of transcription factors  
Transcription factors are highly evolutionarily developd and responsible for 
allowing cells to make quick and appropriate responses to extracellular changes by 
regulating gene expression.  Transcription factors involved in different signaling pathways 
play the key role in multicellular organism development140. Many studies have 
demonstrated that CDK8 is a versatile regulator of several transcription factors. 
C/EBPβ 
The transcription factor CCAAT-enhancer-binding protein β (C/EBPβ) promotes 
gene expression by binding to the target gene promoter and recruiting Mediator 
complex. CDK8 plays two opposite roles under different situations.  
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In vertebrate cells, upon the activation of C/EBPβ mediated transcription, the 
CKM must be replaced by other proteins to remove its inhibitory effect141. Indeed, 
Mediator complex CKM can recruit histone arginine methyltransferase PRMT5 to the 
promoter of C/EBPβ target genes and cause symmetric demethylation of H4 arginine 3 
(H4R3me2s) in the promoter regions of those genes, and consequently transcription 
repression142. In Toll-like receptor 9 (TLR9) mediated innate immune related gene 
expression, C/EBPβ together with CKM are also recruited to the promoter region, 
however, without PRMT5 and no change in H4R3me2s level. Instead, Mediator complex 
with CKM recruits general transcription factors TFIIE and TFIIB and functions as 
transcription activator under these conditions143.   
Β-catenin 
The Wnt/β-catenin pathway plays a vital role in stem cell renewal and 
organogenesis and is activated in many types of cancer144. Cdk8 is capable of 
upregulating β-catenin target gene expression by two ways: directly potentiating β-
catenin mediated transcription and repressing E2F1 which has been shown to restrain β-
catenin activity93,94 
In two RNA interference (RNAi)-based loss-of-function screens in human HCT116 
colon cancer cells, CDK8 was found to activate the canonical WNT/β-catenin pathway93. 
Upon activation, β-catenin transactivation domain directly bound to and recruited 
Mediator complex to Wnt-responsive genes. The direct interaction between β-catenin 
and Mediator complex was mediated by MED12, a key member and stabilizer of CDK8 
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mediator submodule, and ectopic expression of the peptide that mimics the potential β-
catenin binding domain of MED12 disrupted the interaction and inhibited β-catenin 
transcription activity76,145.  CDK8 expression in colon cancer cell lines93 and clinical 
colorectal cancers was correlated with β-catenin activation 146.   
Another explanation of how Cdk8 regulates β-catenin activity comes from studies 
in Drosophila and human cancer cells, in which CDK8 was demonstrated to be bound to 
the transcription factor E2F1 and suppressed the inhibitory effect of E2F1 on β-catenin 
activity94. The binding between E2F1 and CDK8 leads to E2F1 phosphorylation at S375. 
E2F1 with S375 phosphorylation or with S375D mutation loses its inhibitory effect on β-
catenin mediated transcription147.  
STAT1 
Signal transducer and activator of transcription 1 (STAT1), a latent transcription 
factor involved in a variety of biological events, becomes phosphorylated and activated 
by receptor associated kinases upon stimulation by cytokines, such as IFN-γ148. In 
addition to being phosphorylated at tyrosine by its receptor associated kinase, 
phosphorylation at S727 is necessary for STAT1 to achieve its maximal potential in 
transcription induction149. CDK8 has been demonstrated to be the enzyme mediating 
STAT1 S727 phosphorylation in mouse bone marrow-derived macrophages and human 
tumor cells; knockdown of CDK8 by siRNA decreased the transcription of 69% of IFN-γ 
induced genes, involved in antiviral response in mouse MEF cells150. The STAT1 S727 
phosphorylation blockage by CDK8 inhibition has been observed in a variety of human 
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cancer cell lines in cell culture induced by IFN-γ and in xenograft tumors in mouse, and 
has been used as a biomarker for CDK8 inhibitor development151.  
P53 
By meta-analysis of Affymetrix microarray gene expression data of breast cancer 
patients, the expression of CDK8, CDK19 and CCNC at mRNA level was found to be 
strongly increased in tumors with mutant p53152. In fact, CDK8, together with cyclin C and 
MED12 was recruited to p21 promoter, a key target gene of p53, for strong 
transcriptional activation in response to p53-activating stimuli153; knockdown of CDK8 by 
siRNA dramatically decreased Nutlin3 induced p21 expression without changing p53 
level154. In the DNA damage context, CDK8 recruitment to the initiation site was also 
required for p53 mediated p21 induction153. However, the effect of CDK8 on p21 
expression might be kinase independent. This was shown for CDK19 in an osteosarcoma 
cell line (SJSA), naturally lacking CDK8, where knockdown of CDK19 suppressed p53 
target gene expression induced by 5-fluorouracil treatment and this effect could be 
reversed by overexpression of wild type CDK19 as well as CDK19 with D151A or D173A 
kinase-dead mutation79.  
On the other hand, p21 was capable to bind CDK8 and stimulate its activity in 
promoting the secretion of damage- and senescence-related tumor-promoting factors155. 
Knockout of p21 or inhibition of CDK8 kinase activity by Senexin A significantly reduced 
the expression of paracrine tumor-promoting factors induced by doxorubicin treatment 
in HCT116, and inhibition of CDK8 with Senexin A reduced and delayed the formation of 
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tumors in human A549 lung carcinoma mouse xenograft model pre-treated with 
doxorubicin155, suggesting a potential application of CDK8 inhibitors in chemotherapy 
induced relapse and metastasis.  
Notch 
The Notch signaling pathway plays a vital role in cell-cell communications and is 
highly conserved in metazoan evolution156. Notch protein is a transmembrane receptor 
that undergoes proteolysis upon activation leading to the production of a truncated 
peptide, the ICN, which acts as a transcriptional activator in the nucleus. Upon activation 
of Notch1, ICN1 domain is released from Notch 1 by γ-secretase and localizes to the 
nucleus for targeting transcription. CDK8 together with CycC promoted PEST motif 
hyperphosphorylation of ICN1 which caused ubiquitination by Fbw7/Sel10 ubiquitin 
ligase 157,158, and consequently ICN1 was degraded by proteasome system159. 
Interestingly, human T-lineage acute lymphoblastic leukemia is frequently associated 
with PEST domain truncations160; cyclin C gene was deleted in a subset of acute 
lymphoblastic leukemias161. The same mechanism is also observed in SREBP-1c mediated 
transcription. CDK8 bound to and phosphorylated SREBP-1c at T402 and promoted 
SREBP-1c ubiquitination and turnover, and consequently diminished SREBP-1c mediated 
gene transcription in HEK293 cells162.   
HIF1A 
hypoxia-inducible factor 1A (HIF1A) is one of the key transcription factors 
accumulated for gene induction when cells are suffering from hypoxia stress, such as cells 
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in the middle of a rapidly growing tumor but without proper blood vessel formation163. 
CDK8, but not CDK19 was shown to be required for maximum hypoxia induced gene 
expression in HCT116 cells163. By CDK8 chromatin immunoprecipitation sequencing (ChIP-
seq) experiments in HCT116 cells, CDK8 was found broadly bound to the majority of 
promoters of hypoxia induced genes under hypoxic conditions163. Stable knockdown of 
CDK8 did not affect HIF1A binding, histone modification and preinitiation complex (PIC) 
formation in this process, but significantly impaired RNAPII elongation, due to the failure 
of recruitment of positive transcription elongation factor b (P-TEFb) and the formation of 
super elongation complex. In fact, the promoters of hypoxia-inducible genes were 
occupied by paused RNAPII transcription machine, and CDK8-Mediator complex and 
super elongation complex were recruited to chromatin for maximum transcription by 
HIF1A upon activation163. A very similar mechanism has been also observed in the 
regulation of the expression of serum induced immediate early genes. CDK8 was found 
not to be necessary for Pol II recruitment but required for assembly of elongation 
complexes at serum response genes164. 
TFG-β/SMAD pathway 
TFG-β/SMAD pathway is highly involved in multiple biological functions, such as 
embryo development165, tissue homeostasis166 and carcinogenesis167. CDK8 and CDK9 
mediated phosphorylation of linker region of SMADs was observed in embryonic day (E) 
13.5 mouse embryos and in BMP/TGF-β treated mammalian cells. The linker region 
phosphorylation mediated by CDK8/9 recruits YAP, which promotes SMAD1 
transcriptional action, with strong effects on BMP/Smad1 target gene expression168. 
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Interestingly, while potentiating transcriptional activity, phosphorylation of linker region 
by CDK8/9 further triggered additional linker region phosphorylation by GSK3 of SMADs, 
promoting their degradation by Smurf1 mediated ubiquitination168,169. The dual roles of 
CDK8, as potentiator and primer for degradation, provide a good demonstration of the 
strict and finely tuned transcription regulation, which has also been observed in yeast170.  
Effects of CDK8 on metabolism  
Metabolism is one of the most key features of life, through which the organism 
protects life from the law of increasing entropy. CDK8 has been demonstrated to play 
several roles in metabolism regulation (Fig. 1.5).  
Glycolysis  
Inhibition of CDK8 kinase activity by non-hydrolysable ATP analogs in analog-
sensitive CDK8 mutant cells, genetically modified by F97G mutation of CDK8, 
downregulated the expression of many genes involved in the glycolytic pathway.  
Consequently, genetic inhibition of CDK8 kinase activity reduced glucose uptake and 
glycolytic capability in HCT116 cells and sensitized the cells to 2-Deoxy-D-glucose (2DG), 
an inhibitor of glycolysis pathway. Importantly, Senexin A, the dual CDK8/19 inhibitor, 
could partially recapitulate the glycolysis repression role of genetic CDK8 inhibition and 
sensitization of cancer cells to 2DG113.  Consistent with the mammalian model, in 
drosophila starved larvae, CDK8 kinase mutation enhances the expression of genes 





Mitochondria are undergoing fusion and fission dynamically responding to various 
cellular conditions171. Mitochondrial fission divides mitochondrion into smaller units and 
is involved in many biological processes, such as assisting mitochondrial 
neurotransmission in neuron development and mitochondrial degradation in response to 
stress172,173. Cyclin C is required and sufficient for stress-induced mitochondrial fission. 
Knockout of cyclin C showed no effect on mitotic cell division, however, it significantly 
reduced cisplatin induced mitochondrial hyperfission in MEF cells174. Directly introducing 
synthetic glutathione s-transferase-cyclin C fusion protein into CCNC-/- MEF cells resulted 
in significant fragmentation of the mitochondria174. Since CDK8 exclusively localizes to 
the nucleus, it seems not to be involved in the process of mitochondria fission, which 
happens in the cytoplasm174.  On the other hand, CDK19, similarly to cyclin C, is equally 
distributed in both nucleus and cytoplasm and might play a role in cyclin C mediated 
mitochondria fission.  
Lipid metabolism 
The role of CDK8 in lipid metabolism was first observed in drosophila larvae, in 
which lipid accumulated when CDK8 or CCNC was null-mutated. Another experiment in 
drosophila starved larvae also demonstrated that CDK8 kinase-dead mutation increased 
lipid droplets significantly100. A similar phenomenon was also observed in mammalian 
hepatocytes95,162. Knockdown of CDK8 or cyclin C by shRNA significantly upregulated fatty 
acid synthase (FAS) expression at both mRNA and protein levels in HepG2 cells and 
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consequently resulted in triglycerides accumulation. Further studies demonstrated that 
CDK8 could directly phosphorylate SREBP-1 at T402 residue causing degradation of 
SREBP-1 by ubiquitination system; knockdown of CDK8 or cyclin C increased SREBP-1 
protein stability and nuclear distribution in mammalian cells162. In agreement with the 
data in vitro, knockdown of CDK8 in mouse liver via tail vein injection of adenoviruses 
expressing shCDK8 lead to upregulation of FAS and accumulation of palmitate and 
triglyceride162. Interestingly, insulin treatment in vitro or stimulated in vivo via re-feeding 
significantly reduced CDK8 protein levels and upregulated transcription of FAS in vivo 
99,162,175, suggesting an important role of CDK8 in lipid metabolism.     
Autophagy 
Autophagy is a conserved degradative process that provides energy or resources 
to maintain homeostasis under various types of stress, during which macromolecules or 
organelles are engulfed by autophagosomes and hydrolyzed following fusion with 
lysosomes. mTORC1 is in the key position to inhibit autophagy 176 and CDK8 is one of the 
targets of TORC1 and prone to be ubiquitinated and degraded after 
phosphorylation100,101,177.  
A possible role for CDK8 in autophagy can be hypothesized from the evidence 
that CDK8 expression was down-regulated during aging99, while autophagy also declined 
with age178. In mouse liver, autophagy could be induced by starvation179, and CDK8 
protein was increased during this process99.  
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In drosophila, CDK8 and CDC Like Kinase 2 (CLK2) together phosphorylated 
cleavage and polyadenylation specific factor 6 (CPSF6) to regulate mRNA processing 
involved in autophagy. Overexpression of Atg1, the central autophagy regulator, caused 
autophagy in the drosophila eye, with a rough eye phenotype180.  RNAi screen discovered 
that knockdown of CPSF6, a member of cleavage and polyadenylation (CPA) complex, 
could rescue the rough eye phenotype. CPSF6 with CPA complex bind to the 3’ UTRs of 
Atg1 and Atg8a transcript and increase mRNA stability by regulating alternative splicing. 
Further study demonstrated that the activity of CDSF6 was increased by CDK8 and DOA 
mediated phosphorylation. A similar mechanism was also observed in mammalian cells. 
In MCF-7 cells incubated in a starvation medium, knockdown of CPSF6 by shRNA or 
inhibition of CDK8 kinase activity with Senexin A dramatically reduced LC3 puncta and 
formation of lipidated form of LC3 (LC3-II), the necessary step for autophagosome 
formation100. However, CDK8 and CDK19 have not been duplicated in drosophila, an 
event that happened in vertebrates, and Senexin A does not distinguish CDK8 and CDK19, 
suggesting the possibility that it might be CDK19 or CDK19 and CDK8 together that are 
involved in transcript splicing regulation in mammalian cells, especially when the pre-
mRNA splicing related arginine/Serine-rich domain in CDK19 is considered, as descripted 
above105,106. All these data suggest that CDK8/19 could be a key regulator of autophagy 
by regulating specific mRNA alternative splicing and stability. In agreement with this, 
another work performed in drosophila demonstrated that Cdk8/cyclin C were required 




The role of CDK8 in diseases 
CDK8 has been shown to be involved in several diseases, including metabolic 
diseases, neuron related diseases, inflammation diseases, cardiovascular diseases and 
cancer (Fig.1.5). 
 
FIGURE 1.5 The physiological processes and diseases involving CDK8. 
Metabolic syndrome 
Metabolic syndrome refers to the following conditions: insulin resistance, visceral 
adiposity, high blood pressure, dyslipidemia and high body mass index182. The 
insensitivity of the energy detecting system, pancreatic islet insensitive to glucose and  
liver, muscle and adipose tissue insensitive to insulin, is the etiology behind metabolic 
syndrome183, and CDK8 seems to be highly involved in this etiology.  
The expression of CDK8 is upregulated in patients with type 2 diabetes. Screening 
of gene expression in pancreatic islet specimens from type 2 diabetes by microarray 
discovered that CDK8 was highly expressed in diabetic donors relative to normal 
donors184; single nucleotide polymorphism (SNP) map also revealed CDK8 as a potential 
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candidate gene linked to type 2 diabetes185.  However, in contrast with the situation in 
type 2 diabetes, the expression of CDK8 is downregulated in the liver with high fat 
deposition. In the mouse model, CDK8 and Cyclin C protein levels were lower in the liver 
of mice that were fed compared to those that were starved162. In the two mouse models 
with fatty liver, leptin receptor-deficient (db/db) and leptin-deficient (ob/ob) mice, the 
expression levels of CDK8 and Cyclin C were also lower compared to those in wild type 
mice99. The same situation was also found in people with NAFLD, who had lower CDK8 
and Cyclin C expression in the liver99.  
The nutrition related CDK8 expression is regulated via mammalian target of 
rapamycin complex 1 (mTORC1), one of the key nutrient sensor complexes186.  In rat 
hepatoma FAO cells, nutrient-depletion decreased CDK8 expression, however, treatment 
with mTORC1 inhibitors, Rapamycin and Torin 1, both effectively prevented nutrient-
depletion induced down-regulation of CDK899. Liver specific Raptor knockout mice 
showed significantly higher CDK8 compared with wild-type mice that were re-fed after 
fasting. Inhibition of mTORC1 also reversed aging induced CDK8 down-regulation in 
mouse liver99. Taken together, mTORC1 can down-regulate CDK8-Cyclin C in certain 
physiological conditions and this regulation plays an important role in the metabolic 
balance. 
Cardiovascular disease 
According to Centers for Disease Control and Prevention, heart disease is the 
primary cause of death in the United States. CDK8 plays a role in cardiovascular disease in 
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two aspects: by acting directly on cardiomyocyte development and by acting indirectly on 
lipid biosynthesis. Transgenic mice with specific overexpression of CDK8 in 
cardiomyocytes had enlarged atria and dilated ventricles and died prematurely with the 
symptoms of heart failure (HF). Cardiomyocytes from CDK8 transgenic mice were longer 
but thinner than from the wild type mice, the typical morphology change in progressive 
dilated cardiomyopathy and consequently HF187.  
Dyslipidemia has been well demonstrated to be related to cardiovascular 
disease188-190. The SREBP transcription factors play central roles in the regulation of lipid 
biosynthesis and are conserved in evolution191,192. CDK8 phosphorylated SREBP1 protein 
at T402, which resulted in proteasome-mediated degradation of SREBP1 and repressed 
lipid-synthesis related gene expression. Specifically, knockdown of CDK8 in liver by tail 
vein injection of adenovirus expressing shRNA against CDK8 caused accumulation of 
triglycerides in liver and in plasma162. Interestingly, re-feeding significantly decreased 
CDK8 and cyclin C in the nuclei and upregulated nuclear SREBP-1c level, suggesting the 
involvement of CDK8 in nutrient related gene regulation162. In a naturally CDK8 depleted 
cell line, knockdown of CDK19 significantly enhanced expression of genes related to lipid 
and steroid biosynthetic process79.  
In addition to CDK8, other members of CKM are also involved in cardiovascular 
disease. Missense mutation of MED13L has been observed in patients with congenital 
heart defect (transposition of the great arteries)193. In a mouse model, Med12 
hypomorphism caused cardiac malformations and embryonic lethality at E10.5194.  
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Diseases of Neural system 
A case study showed that CDK19 was disrupted in a female patient with 
congenital retinal fold and microcephaly and was believed to be the causative factor110. 
Since CDK8 and CDK19 diverge only in vertebrates, the roles of both CDK8 and CDK19 in 
vertebrates are believed to be substituted by CDK8 in lower level organisms. In 
drosophila dendritic cells, related to mental retardation in the fly model, knockdown of 
CDK8 dramatically reduced dendritic branching110. In another drosophila model, by 
genetic mapping using single nucleotide polymorphisms, CDK8 was discovered to be 
associated with visual system wiring195. CDK8 kinase mutation in drosophila resulted in 
thicker and darker bristles, sensor for air flow on legs 77. In C. elegans, CDK8 and other 
proneural proteins were necessary for neurogenesis from a presumptive mesoderm-
derived cell lineage131, and also required for proper axon navigation during 
development196 . 
According to an immunohistochemical study, Cyclin C was weakly expressed in 
both neurons and astrocytes from the brain, however, strong staining was detected in 
astrocytes and pyramidal neurons in Alzheimer’s Disease (AD), implying its possible role 
in AD pathogenesis197. Altered Pol II CTD phosphorylation status and subcellular location 
has been discovered in biopsy specimens from Alzheimer’s disease (AD) brains198.  
Mouse with Med12 hypomorphic mutation died at embryonic day 10 with severe 
defects in axis elongation and neural tube closure194. In patients, MED13L variants were 
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associated with intellectual disability199, and mutations that affected MED13 function 
were observed in patients with developmental delay and/or intellectual disability200.   
Inflammation  
Inflammation is a type of biological responses of body tissues to various stimuli 
and it contributes to many normal physiological and pathological processes, such as 
wound healing and cancer201.  Interleukin 10 (IL10), a broadly expressed anti-
inflammatory cytokine202, has been proven to be negatively regulated by CDK8/19. 
Through high-throughput assay a compound designated BRD6989 was found to enhance 
IL-10 production in bone-marrow-derived dendritic cells (BMDCs) stimulated with 
zymosan A. Kinome profiling identified CDK8, but not other kinases, as the BRD6869 
specific target. Other CDK8/19 inhibitors, such as cortistatin A and CCT251921, 
recapitulated the enhancing effect on IL-10 induction in BMDCs at reasonable 
concentrations203. As a strong immune homeostasis regulating cytokine, recombinant IL-
10 coupled with other treatments has shown promising results in clinical trials for 
Crohn’s disease and rheumatoid arthritis204,205. While the anti-inflammatory cytokine IL10 
was upregulated upon CDK8/19 inhibition, IL8, a proinflammatory cytokine, was 
downregulated upon CDK8/19 kinase inhibition by a series of specific inhibitors in co-
culture models206.   
Activation of Toll-like receptor 9 (TLR9) by oligonucleotides(ODN) containing 
unmethylated CpG motifs(ODN2006), mimic bacterial DNA, strongly activate NF-κB 
signaling pathway and expression of inflammatory cytokines in myeloma-derived 
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RPMI8226 cells. CDK8/19 and NF-κB together with other essential transcription factors 
colocalized on the promoters of inflammation-associated genes upon ODN stimulation 
and knockdown of CDK8/19 by siRNA largely abolished TLR9 agonist induced 
inflammatory cytokine expression143. CDK8/19 also plays an important role in TNFα /NF-
κB induced gene expression. Inhibition of CDK8/19 kinase activity by Senexin A or Senexin 
B strongly depressed the early response gene expression induced by TNFα or IL-1, by 
impairing elongation of transcription207. In addition, CDK8/19 was also found to be 
necessary for human papillomavirus type 16 late gene expression by regulating 
transcriptional elongation208.  
All the above information suggests that CDK8 might be a good target for 
inflammation control, by inducing anti-inflammatory cytokines and repressing TNFα /NF-
κB pathway activity. 
Cancer 
According to the Cancer Facts & Figures published by American Cancer Society, 
cancer ranks second among the common causes of death in the US. CDK8/19 has been 
demonstrated to be positively involved in the development of many types of cancer, such 
as  melanoma82, gastric adenocarcinoma209, colorectal cancer93,146, laryngeal squamous 
cell carcinoma210, papillary thyroid211, pancreatic cancer212 and breast cancer213, and 
others. Pathological specimen analysis demonstrates that CDK8 expression in colorectal 
cancer and CDK19 expression in prostate cancer are highly elevated (Fig 1.6). We will 
review the roles of CDK8/19 in different cancer phenotypes. 
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Cancer promoting role of CDK8 
Proliferation 
The most important characteristic of cancer is uncontrolled growth of abnormal 
cells. Dysregulation of Wnt/β-catenin pathway is implicated in the majority of colon 
cancers. CDK8 was identified as a potentiator for Wnt/β-catenin pathway by two RNAi-
based loss-of-function screens93. Overexpression of CDK8 but not CDK8 harboring kinase-
dead mutation transformed NIH-3T3 cells and knockdown of CDK8 was reported to 
dramatically inhibit the growth of HCT116 cells and other CDK8-overexpressing colon 
cancer cell lines 93. 
 
 
FIGURE 1.6 The expression of CDK8 and CDK19 in different types of cancer. 
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RNA-seq data of 17 cancer types are reported as median FPKM (number 
Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome 
Atlas (TCGA). 
 
Instead of CDK8, CDK19 was usually upregulated in prostate cancer cell lines 
compared to benign prostate RWPE cells214. Simultaneous knockdown of CDK8 and 
CDK19 significantly suppressed the proliferation in one of the tested prostate cancer cell 
lines, VCaP 215. 
Among all the studied malignancies, the activity of CDK8 was found to be the 
most crucial for a subset of acute myeloid leukemias (AML). Inhibition of CDK8 kinase 
activity with Cortistatin A dramatically decreased the growth of a subset of AML cell lines; 
the specificity of the anti-proliferation effect of Cortistatin A was confirmed by CDK8/19 
W105M mutation, which maintained kinase activity but produced resistance to inhibition 
by Cortistatin A, and consequently the anti-proliferation effect of CA was obliterated in 
W105M mutant AML cells139.  
In contrast to proliferation promoting role in the above examples, knockdown of 
CDK8, using CRISPR technology, did not significantly change cell growth in HPV16-
containing keratinocytes208. Knockdown of CDK19 or CDK8 via siRNA did not reduce 
proliferation of prostate cancer cells, but reduced cell migration (VCaP was not tested in 
that study)214.  In addition to these findings, most of the developed CDK8/19 inhibitors 
failed to recapitulate the growth repression effect in HCT116 colon cancer cells at 
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concentrations that were effective in suppressing STAT1-s727 phosphorylation139,155,216, 
and knockout of CDK8 and CDK19 did not show any effect on HCT116 cell viability 216. 
The seemingly contradictory effects of CDK8 on cell proliferation might stem from 
the variability of cell lines. The distribution of β-catenin seems to influence, at least in 
certain models, the effect of CDK8 on cell proliferation.  HCT116 cells are heterozygous 
for a β-catenin mutation that confers resistance to degradation and are believed to be β-
catenin dependent217. However, under normal growth conditions, the majority of β-
catenin is distributed in the cytoplasm in HCT116 and HT29 cells while in SW480 and 
DLD1 cells, most of the β-catenin stays in nucleus218-220. In agreement with this, our data 
showed that inhibition of CDK8 with Senexin B had little effect on the growth of HCT116 
and HT29 cells but significant growth inhibition over the long term was observed in 
SW480 cells.  
Dedifferentiation 
Dedifferentiation, as a hallmark of many malignant tumors, refers to the tumor 
cells bearing little or no resemblance to the cells that they originate from, a kind of 
reverse differentiation221. Those tumors that highly express embryonic stem cell related 
genes are usually poorly differentiated and have a poor clinical outcome222. CDK8 is 
required for colon cancer cells to maintain dedifferentiation status. Inducible knockdown 
of CDK8 in the mouse xenograft model of human colon cancer cell lines not only 
significantly inhibited tumor growth but also induced tumor cell differentiation, 
represented by more organized glandular structure and secreted mucin223. Interestingly, 
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the expression of CDK8 decreased as normal mouse embryonic stem cell differentiated; 
overexpression of CDK8 was capable of reversing mouse embryonic stem cell 
differentiation by upregulating and activating MYC, implying a mechanism through which 
high CDK8 expression induces tumorigenesis223. In agreement with these findings, 
depletion of Mediator kinase module subunits, especially MED12 and MED13/13L, 
resulted in downregulation of the expression of cancer-acquired super-enhancer 
containing genes in colon cancer76. Correspondingly, in AML cell lines, only the cells with 
a high level of stem cell related gene expression were sensitive to CDK8 inhibitor 
treatment224.  
EMT 
Epithelial to mesenchymal transition (EMT), first described in embryonic 
development, has been shown to play important roles in tumorigenesis, drug resistance 
and metastasis225. In pancreatic cancer samples and cancer cells, CDK8 expression was 
upregulated by K-ras activating mutation and was involved in EMT in pancreatic cancer. 
Knockdown of CDK8 by shRNA neutralized the K-ras mutation induced EMT by regulating 
EMT related gene expression in Wnt/β-catenin signaling pathway226. In addition, CDK8 
protein levels were positively correlated with lymph node metastasis in laryngeal 
squamous cell carcinoma (LSCC) patients; knockdown of CDK8 by siRNA expressing 
lentivirus significantly repressed human LSCC cell migration and upregulated E-cadherin 
expression, a hallmark of EMT changes227. Recently, selective inhibition of CDK8/19 by 
Senexin B has been shown to abrogate BMP-induced EMT in a wide spectrum of cancer 
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models, with downregulation of EMT-associated transcription factors and enhanced E-
cadherin expression both in vitro and in vivo228.  
Metastasis 
About 90% of cancer death is caused by metastasis and conquering metastasis 
would be the key to treating cancer229. Genome-wide chromosomal copy number 
alteration analysis comparing paired primary and liver metastatic colorectal tumors 
discovered amplification of CDK8 in some liver metastatic tumors while no amplification 
was found in the paired primary tumors230; in clinical colorectal adenocarcinoma analysis, 
CDK8 expression was significantly positively correlated with lymph node metastasis or 
distant metastasis231.  CDK8 expression was also upregulated in human LSCC compared to 
normal controls and overexpression of CDK8 was positively correlated with lymph node 
metastasis and significantly shorter overall survival227. Consistently, miR-101, targeting 
CDK8, was downregulated in LSCC tissues and negatively correlated with tumor grade 
and lymph node metastasis; overexpression of miR-101 suppressed LSCC Hep-2 cells 
proliferation and migration210. CDK8 was also found to be positively correlated with 
carcinogenesis and tumor progression, especially lymph node metastasis in gastric 
adenocarcinoma209. Additionally, in diethylnitrosamine (DEN)-induced liver cancer model, 
miR-26a, targeting CDK8, when administered by AAV-delivery system significantly 
reduced lung metastasis92. While there was no effect on cell proliferation, knockdown of 
CDK8 or CDK19 in prostate cancer cell lines significantly repressed the invasion and 
migration in trans-well experiments214. In fact, CDK19 expression was higher in metastatic 
prostate tumors than in paired primary tumors and was associated with unfavorable 
46 
 
prognosis214. In another study, selective depletion of CDK8 in natural killer (NK) cells 
significantly reduced B16F10 mouse melanoma cells lung metastasis, as measured by 
pulmonary tumor nodules per lung.  
Immune surveillance 
As discussed above, CDK8 is one of the key kinases that are responsible for basal 
phosphorylation of STAT1-S727, including NK cells232. Mutation of the phosphorylation 
site (STAT1-S727A) targeted by CDK8 robustly enhanced in vitro-expanded NK cell 
cytotoxicity toward leukemic cells. In addition, mice harboring STAT1-S727A mutation 
survived significantly longer than STAT1-/- and wild-type mice when intravenously 
transplanted with v-abl-transformed leukemic cells232. Through enhanced tumor 
surveillance, STAT1-S727A mice were highly resistant to 4T1 breast cancer metastasis232. 
In accordance with these data, conditional ablation of CDK8 in NK cells enhanced NK-cell 
cytotoxicity in vitro and improved tumor surveillance in vivo. Mice with CDK8-deficient 
NK cells were more resistant to  v-abl+ lymphoma, and Abelson Murine Leukemia virus 
(A-MuLV)-induced slowly progressing pro-B cell leukemia, and B16F10 melanoma 
metastasis233. It should be noted that ablation of CDK8 did not influence NK cell 
development and proliferation233, suggesting limited side effects by targeting CDK8 in NK 
cells.  
Warburg effect 
Warburg effect, in oncology, refers to the fact that most cancer cells produce 
energy through inefficient anaerobic glycolysis instead of through mitochondrial 
47 
 
oxidative phosphorylation. Warburg effect has been studied in the field of oncology for 
almost a century, and its fundamental roles in tumor development have been established 
by myriads of studies234. By comparing colon cancer cells with hypomorphic alleles 
sensitive to a bulky adenine analog, created by a single point mutation in the kinase 
pocket of CDK8, to wild type cells, treated with ATP analogs, CDK8 kinase activity was 
found to increase the expression of many key components involved in glycolytic pathway. 
CDK8 inhibition decreased glycolytic capacity as well as glucose transporter expression 
and glucose uptake as a consequence. Importantly, CDK8/CDK19 specific inhibitor 
Senexin A sensitized cells to pharmacological glycolysis inhibition, showing significant 
synergy with 2-Deoxy-D-glucose treatment113, suggesting that CDK8 might be a potential 
pharmacologic target for the treatment of tumors with impeded glycolysis.  
Drug resistance 
Drug resistance usually develops to both conventional and targeted cancer 
therapies and is the reason why about 90% of chemotherapy fails235. Transcription 
dysregulation is one of the main factors behind drug resistance in cancer236. CDK8 has 
been demonstrated to be a promising target for estrogen receptor (ER)-positive breast 
cancer, in both ER-targeting therapy drug resistance and ER-targeting drug potentiation 
ways.  Under estrogen depleted conditions, inhibition of CDK8/19 with Senexin B 
dramatically suppressed the development of estrogen independence in  ER-positive 
breast cancer cells; inhibition of CDK8/19 by Senexin B also boosted the anti-tumor effect 
of ER-inhibiting drugs on ER-positive breast cancer cell proliferation in vitro and xenograft 
tumor growth in vivo213,237.  Similarly, down regulation of CDK8 mediated by miR-107 
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sensitized A549 non-small cell lung cancer cells to cisplatin89. Knockdown of CDK19 
significantly improved nutlin-3 induced cell growth inhibition in SJAS cells, in which CDK8 
expression was lacking;  this effect was kinase activity independent, since it could be 
reversed by overexpression of CDK19-D151A or CDK19-D173A and could not be 
mimicked by Cortistatin A79.   
Cachexia 
Cachexia is one major cause of cancer-associated death, occurring in about 80% 
of cancer patients238. Cancer cachexia is characterized by massive loss of body mass, 
including the wasting of skeletal muscle, cardiac muscle and lipids238,239. TNFα was the 
first cytokine identified in relation to cachexia and named as “cachectin” to emphasize its 
important role in cachexia240,241. The role of TNFα in cachexia is primarily exerted through 
the NF-κB pathway, activation of which reduces the cellular levels of MyoD protein and 
inhibits myoblast terminal differentiation242,243. In fact, inhibition or ablation of NF-κB 
signaling pathway by genetic methods or by chemical compounds significantly 
ameliorated muscular dystrophy in several models244-246. CDK8/19 kinases, as mentioned 
above, are required for full activation of NF-κB signalling pathway. Inhibition of CDK8/19 
strongly suppresses the expression of early response genes induced by TNFα, with IL8 as 
one of the most induced genes in almost all the tested cell lines207. Interestingly, specific 
polymorphisms and upregulated expression of IL8 gene have been strongly associated 
with cachexia in gastric, prostate and lung cancers247-250.   
Sarcoma in fish 
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In a very unique model, walleye dermal sarcoma virus infection causes seasonal 
development and regression of dermal sarcoma in fish. The retroviral cyclin encoded by 
walleye dermal sarcoma virus selectively enhanced CDK8 activity but did not change 
CDK8 the spectrum of CDK8 target genes, which contributed to the oncogenic capacity of 
walleye dermal sarcoma virus251.  
Potential tumor-suppressive effects of CDK8 
A potential tumor-suppressive role of CDK8 was suggested in endometrial cancer 
cells based on the following observations: overexpression of CDK8 inhibited endometrial 
cancer cell growth and migration while inhibition of CDK8 in endometrial cancer cells 
promoted their growth and migration252. The tumor-suppressive effects of CDK8 in 
endometrial cancer was suggested to be due to the fact that inhibition of CDK8 
dramatically induced lipid synthesis which positively correlates with endometrial cancer 
progression253. However, the methods of gene modification applied in that paper require 
special attention, as the shRNA targeting GFP, used as the negative control in that study, 
can be toxic to cells (as noted in our laboratory); and the activity of ectopically 
overexpressed CDK8 was not verified.   
In the Apc(Min) murine model, conditional depletion of CDK8 in intestinal 
epithelium driven by villin promoter induced Cre expression enhanced tumor 
aggressiveness, with no change in the number of developing tumor foci254. The authors 
suggested, however, that this result need not be interpreted as a tumor-suppressive 
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function of CDK8, but rather as evidence that tumors arising despite the lack of CDK8 
could acquire a more aggressive phenotype in the course of carcinogenesis254. 
In another study, ablation of Cyclin C impaired CDK8/19 kinase activity and caused 
Notch1 intracellular domain (ICN1) hypophosphorylation; the phosphorylation of ICN1 
was required for its degradation and activity under control255. knockout of cyclin C 
resulted in upregulation of ICN1 and increased the number of thymocytes in the mouse 
model; heterozygous cyclin C deletion enhanced T-ALL development in the Lck-LMO1 
transgenic mice, identifying Cyclin C as a haploinsufficient tumor suppressor in T-cells158.  
Somatic MED12 mutations that impaired Mediator complex kinase activity or 
interaction between MED12 and other Mediator complex components were observed in 
uterine leiomyomas256,257 and prostate cancer258. Frequent somatic mutations in exon 2 
of MED12 occur in uterine fibroids, which disrupt allosteric activation of CDK8 and CDK19 
in subcomplex module259.  Significant mutations of MED12 that lead to CDK8/19 
dissociation from core Mediator were observed in Chronic lymphocytic leukemia (CLL) 
and such mutations were associated with poor prognosis260.  
CDK8/19 as a target for drug development 
Kinase inhibitors are one of the major areas in drug development261.  For most of 
the protein kinases, the “Asp-Phe-Gly (DFG)” motif, located at the beginning of the 
activation loop, is highly conserved and plays the key role in the regulation of kinase 
activity262.  When the kinase is in active status, the DFG motif adopts the “in” 
conformation, with the Asp residue flipped inward, which is favorable for the 
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coordination of magnesium ion and ATP binding; when the kinase is in inactive status, the 
DFG motif changes its conformation to the “out”, with the Asp residue oriented outward 
and no longer favorable for the coordination of magnesium at the catalytic site262,263. 
Corresponding to the DFG motif conformations, two main kinds of kinase inhibitors are 
developed: type I inhibitors bind to the active conformation of the protein kinase and are 
ATP-competitive264; type II inhibitors bind to the inactive confirmation of the protein 
kinase and allosterically stabilize the catalytically inactive conformation263,264.  
For most of the CDKs, the DFG region does not perform “in” and “out” structural 
transition, exhibiting DFG “in” conformation in both active and inactive status265. As a 
result, most of the inhibitors of CDKs are type I inhibitors.  However, sorafenib has been 
shown to bind to CDK8 catalytic cleft and then induced and stabilized a DMG “out” 
confirmation of CDK8, equal to the DFG “out” confirmation in other kinases266. One thing 
that should be noted is that type I CDK8 inhibitors usually give significant inhibition of 
STAT1 S727 phosphorylation, but type II CDK8 inhibitors exhibit weak potency in the 
inhibition of STAT1 S727 phosphorylation in cells267,268. Therefore, STAT1 S727 
phosphorylation might not be a proper molecular marker for cell-based testing of type II 
CDK8 inhibitors. Until now, most of the type II CDK8 inhibitors, such as sorafenib, linifabib 
and the recently developed CCT251545268, are not specific enough, with broad off-target 
kinase inhibition activities151,267.   
Compared to the preimplantation embryonic death in CDK8 knockout mice, no 
gross or histopathological abnormalities were observed in conditional CDK8 knockout in 
young adult mice254 and NK cell-specific CDK8 knockout of mice233, suggesting that CDK8 
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inhibition should have little toxicity. Many CDK8/19 inhibitors have now been developed 
(Table 1). Several CDK8 inhibitors were discovered by cell based screening, such as 
CCT251545 that was identified via WNT signaling dependent TCF-luciferase expression in 
HEK293 cells268,269; Senexin A was identified by screening for inhibitors of p21-activated 
transcription155. Nowadays, computer-aided drug design has been widely applied for 
kinase inhibitor discovery. Three CDK8 inhibitors were computationally screened out 
from a large library of drug-like molecules by using two complementary cascades virtual 
screening methods270.  Compound 16 was discovered trough Fragment-based drug 
discovery (FBDD), through which the drug’s potency had been highly improved by 
fragment modification based on the structure activity relationship (SAR)271. Compound 
51 was derived from CCT251545 by scaffold-hopping and introduction of  an amino 
substituent to prevent oxidase-mediated metabolism, and demonstrated prolonged half-
life in  animal model272. By modifications at the morpholine moiety, Compound 4k turned 
out to be resistant to deactivation and metabolism mediated by CYP3A4273, a member of 
cytochrome P450 superfamily of enzymes274.  
Considering the data from CDK8 conditional knockout model, more specific 
CDK8/19 inhibitors, with fewer off-target effects on the host, will be continually 
developed. In the future, CDK8/19 inhibition sensitive cancer cell lines should be selected 
and applied for testing the therapeutic window of drugs in animal models. As discussed 
above, other diseases besides cancer, such as Inflammatory bowel disease, diabetes and 
cardiovascular disease, should also be considered as potential targets of CDK8/19 
inhibitors, and side effects on the neural system should be carefully checked. 
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Table 1.1 CDK8/19 inhibitors in development 
 
inhibitor IC50 in vitro  Biological effect test  Reference  
Compound 
4K 





Inhibit pSTAT1-727 with EC50 8.4 nM. 
Suppress tumor growth (T/C 29%) in 
RPMI8226 mouse xenograft model 
273 
T-474 CDK8 = 1.6 
nM 




animal study  
Inhibit the growth of prostate tumor in 








Enzyme activity-based test 271 
W-34 CDK8 = 6.5 
nM 





CDK8 = 50 
nM 
 Shows antimicrobial activity. 
Inhibits the growth of HCT116 cell  
276 





Inhibit the growth of a group of AMLs in 
xenograft model.  
 
224 






Inhibition of STAT1 phosphorylation and 
suppress tumor growth (T/C 1%) in 
RPMI8226 mouse xenograft model 
277 





Suppresses STAT1 S727 phosphorylation and 















Inhibition of STAT1 phosphorylation and 
weak antiproliferative activity in HCT116 
cells 
216 
CCT251921 CDK8 = 2.3 
nM 
CDK19 = 2.6 
nM 










CDK8 = 5.1 
nM 




life in vivo 
Sustained inhibition of STAT1-727 
phosphorylation in SW620 xenograft model 




CDK8 = 10 
nM 
Orally bioavailable  Sustains inhibition of STAT1-727 
phosphorylation in SW620 xenograft model 
following single oral dosing. 
280 




291 other kinases 
inhibits STAT1-727 phosphorylation in colon 
cancer cell lines. 
 Suppresses growth of WNT-dependent 
tumors. 
268 
Cortistatin A CDK8 = 12 
nM 
 Reduces proliferation of JAK2-mutant AML 
and most myeloproliferative neoplasms in 
vivo. 
Suppresses Tat-dependent HIV transcription 




Senexin A  CDK8 = 280 
nM 
Highly selective Delays NICD degradation in NOTCH1 mutant 
CLL.  
Decreases migration and invasion of prostate 
cancer cells. Suppresses tumor growth of ER-
positive breast cancer xenografts. Inhibits 
chemotherapy-induced tumor-promoting 








CHAPTER 2 RATIONALE OF THE INVESTIGATION 
As mentioned before, it has been demonstrated that CDK8 is amplified and/or 
overexpressed in a large fraction of colorectal adenocarcinomas146,231 and knockdown of 
CDK8 by shRNAs was reported to suppress the growth of colon cancer cell lines that 
harbored CDK8 copy number gain. The suppressing effect could be reverted by 
overexpression of wild type CDK8 but not of CDK8 with kinase domain mutation93, 
suggesting a kinase-dependent cell growth effect of CDK8. However, while a few drugs 
developed to target CDK8 kinase activity showed an effect on colon cancer cell growth, 
the majority of such drugs, including Senexin A and Senexin B developed by our lab, 
exhibited little or no effect on colon cancer cell growth in vitro.  Considering the 
concentrations of drugs applied for in vitro experiments, more than hundred times higher 
than IC50, and the potential off-target effects, not only on kinases but also on other 
processes involved in cell proliferation, the probability of CDK8 kinase inhibition 
restraining colon cancer cell growth seemed unlikely. On the other hand, higher CDK8 
expression in the clinical colon cancer samples, detected by immunohistochemistry, was 
associated with a poor prognosis146, implying that reduction of CDK8 expression might be 
a method to improve survival of colon cancer patients. Putting all the information 
together, the seemingly contradictory information raises two fundamental questions, a) 
Do the inhibition of CDK8 kinase activity and depletion of CDK8 itself have the same 
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influence on the growth of colon cancer cells; b) Is the unfavorable role of CDK8 in colon 
cancer patients related to the growth of tumors at the primary site or to other reasons, 
such as metastasis?   
To address question a), we applied two separate approaches to inhibit CDK8 
kinase activity and decrease CDK8 protein itself. CDK8 kinase activity can be inhibited by a 
potent and selective CDK8 inhibitor, Senexin B, a Phase I clinical drug candidate (Fig. 2.1). 
CDK8 protein knockdown can be performed by introduction of shRNAs into the target 
cells. The growth of tumor cells, treated with Senexin B and/or with CDK8 knockdown by 
shRNAs, will be investigated in vitro and in vivo, subcutaneously, orthotopically for 
primary tumor model and in the liver for metastatic model.   
With the data generated by the above studies, the molecular mechanisms behind 
the experimental phenomena  that will show significant changes upon CDK8 inhibition 
will be investigated by high-throughtput microarray analysis and confirmed by qPCR and 
western blotting. To validate the candidate signal pathways that are involved in CDK8 
related biological phenomena, expression modification of the pertinent genes, 
knockdown by shRNA or overexpression by corresponding full-length cDNA vextors, will 





FIGURE 2.1 Inhibitory effect of Senexin B on 451 kinases. 
Kinome profile was determined by ATP analog binding competition assay.  Inhibited 
kinases are marked with red circles and circle size is proportional to percentage inhibition 






CHAPTER 3 EXPERIMENTAL RESULTS 
Inhibition of CDK8 does not block colon cancer cell proliferation in culture.  
CDK8 is frequently amplified in colon cancers 286, and elevated CDK8 protein was 
associated with increased colon cancer specific mortality 287. Since CDK8 or its paralog 
CDK19 function in complex with cyclin C (CCNC), MED12 and MED13 151, we used 
SurvExpress RNASeq database to investigate whether CDK8, CDK19, CCNC, MED12, 
MED13 and MED13L (a paralog of MED13) are differentially expressed between equal-
size high-risk and low-risk populations of 797 colon cancer patients. Most of these genes, 
except CCNC and MED12, were expressed at much higher levels in the high-risk group, 
with CDK8 showing the greatest differential (Fig 3.1A). Kaplan-Meyer analysis showed 
shorter disease-specific survival of patients with highest CDK8 RNA expression (Fig. 3.1B), 
in agreement with previous protein studies 287.  
We analyzed the effects of CDK8/19 inhibition on in vitro growth of three CDK8-
overexpressing human colon cancer cell lines: HT29 and SW480 where CDK8 gene is 
amplified and HCT116 where CDK8 is overexpressed without amplification 286. CDK8 
knockdown in these cells has been associated with decreased proliferation 286 but several 
CDK8/19 kinase inhibitors failed to suppress their growth 288-290. We treated these cell 
lines with a highly selective CDK8/19 kinase inhibitor Senexin B 291, which inhibits the 
growth of leukemias 224 and breast cancers 213. 5-day treatment with 1 M Senexin B
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(corresponding to ~20 times IC50 in cell-based CDK8 activity assays) did not inhibit the 
growth of any cell line (Fig. 3.2A). In contrast, STAT1 phosphorylation at S727, which is 
exerted in part by CDK8 292, was decreased by Senexin B (Fig. 3.2B). We have also carried
 out long-term (14-day) colony formation assays. 1 M Senexin B did not decrease 
the colony number in HCT116 and HT29 compared to vehicle control (Fig. 3.2C,D) but 
image analysis showed that average colony size was moderately reduced (1.39-fold in 
HCT116, 1.85-fold in HT29). In contrast, SW480 (Fig. 3.2E) showed a decrease in both 
colony number (4.47-fold) and size (2.78-fold) upon Senexin B treatment. Hence, CDK8 
kinase inhibition in CDK8-overexpressing colon cancer cells does not affect cell 
proliferation in the short term but moderately inhibits long-term cell growth in some cell 
lines. 
 
FIGURE 3.1 CDK8 expression correlates with colon cancer survival. 
 (A) Expression of Mediator-associated CDK module components in equal-sized 
high-risk and low-risk groups of 797 colon cancer patients (RNA-Seq data from 
SurvExpress). (B) Association of CDK8 expression with disease specific patient survival in 




Stable CDK8 knockdown in HCT116 and HT29 reduced cell growth in prior studies 
286. However, establishment of stable CDK8 knockdown derivatives could involve 
additional changes; indeed, HCT116 cells with CDK8 overexpressed CDK19 293. To avoid 
changes associated with cell selection, we introduced CDK8-targeting shRNA into HCT116 
cells using a doxycycline-inducible vector. Doxycycline treatment decreased CDK8 
expression in these cells, with no effect on CDK19 (Fig. 3.2F), but did not inhibit cell 
growth in a 5-day proliferation assay (Fig. 3.2G). In 14-day colony formation assays (Fig. 
3.2H), doxycycline-induced CDK8 shRNA expression had minor effects on the colony 
number (1.06-fold) and average colony size (1.22-fold).  
CDK8 inhibition selectively suppresses colon cancer growth in the liver.  
As the primary model for in vivo studies, we used murine CT26 colon cancer cells, 
which form syngeneic tumors in Balb/c mice. CT26 carry a G12D KRAS mutation, 
homozygous deletion of CDKN2A and are wild-type for APC and TP53 294 but Wnt/β-
catenin responsive 295.  Treatment with 1 M Senexin B did not inhibit CT26 growth in 
short-term culture (Fig. 3.3A), despite inhibition of STAT1S727 phosphorylation (Fig. 3.3B) 
(CT26 do not form colonies). We introduced two different CDK8 shRNAs (to control for 
off-target effects) into CT26 cells, which robustly express CDK8 but not its isoform CDK19 
(Fig. 3.3C); stable knockdown of CDK8 alone had no effect on the low CDK19 expression 
(Fig. 3.3C). Both CDK8 shRNAs gave only modest (statistically insignificant) growth 
inhibition in vitro relative to control cells expressing either insert-free vector or 





FIGURE 3.2 inhibition of CDK8 does not affect colon cancer cell proliferation. 
(A) Effect of 1 M Senexin B on the growth of human colon cancer cell lines; cell 
numbers measured in triplicates. (B) Effects of 3 hr treatment with 1 M Senexin B on 
STAT1S727 phosphorylation and expression of STAT1 and CDK8 in human colon cancer cell 
lines. (C-E) Effects of 1 M Senexin B on colony formation by HCT116 (C), HT29 (D) and 
SW480 (E) cells (14 days, in triplicates), colony numbers are indicated. (F) Effects of 
doxycycline-inducible shRNA expression (96 hr treatment with 1 μg/mL doxycycline) on 
the expression of CDK8 and CDK19 RNA (qPCR) and proteins (inset) in HCT116 cells. (G) 
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Effects of 1 μg/mL doxycycline on the growth of HCT116 cells with doxycycline-inducible 
CDK8 shRNA; cell numbers measured in triplicates. (H) Effects of 1 μg/mL doxycycline on 
colony formation by HCT116 cells carrying doxycycline-inducible CDK8 shRNA (14 days, in 
triplicates). 
We tested the effects of CDK8 knockdown and Senexin B treatment on in vivo 
growth of cells implanted subcutaneously (s.c.) in BALB/c mice and found only weak 
effects on tumor growth (Fig. 3.3E-H). CDK8 knockdown also had no effect on tumor 
growth in an orthotopic model (cecal injection) (Fig. 3.3I,J).  
 
FIGURE 3.3 Effects of CDK8 inhibition on CT26 murine colon cancer growth. 
(A) Effect of 1 M Senexin B on the growth of CT26 cells; cell numbers measured 
in duplicates. (B) Effects of 3 hr treatment with 1 M Senexin B on STAT1S727 
phosphorylation and expression of STAT1 and CDK8 in CT26 cells. (C) Effects of CDK8 
knockdown by two shRNAs (shCDK8-1 and shCDK8-2) on the expression of CDK8 and 
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CDK19. pLKO.1 insert-free vector was used as a control (CT26-pLKO.1). Knockdown was 
confirmed by qPCR and immunoblotting (inset; CDK19 was undetectable by 
immunoblotting). (D) Cell growth of control CT26 cell lines (CT26-pLKO.1 and CT26-
scramble) and CT26 cells with CDK8 knockdown (shCDK8-1 and shCDK8-2), cell numbers 
measured in duplicates. (E,F) Effect of CDK8 knockdown on the growth of s.c. tumors 
relative to CT26-pLKO.1 (control) (n=10). Tumor growth curve(E) and final tumor 
weights(F) are shown (G,H) Effects of treatment with Senexin B on the growth of s.c. CT26 
tumors. Mice received Senexin B (oral, b.i.d.) or vehicle control (n=10) when the tumor 
volume reached ~200 mm3. Tumor growth curve(G) and final tumor weights(H). (I,J) Effect 
of CDK8 knockdown on orthotopic tumor growth (cecal injection) relative to pLKO.1 
(control) (n=10). Mice were euthanized 30 days after injection. Representative tumor 
images (I); final tumor weights (J).  
To evaluate the effects on metastatic tumor growth in the liver, we used a splenic 
injection model, where tumor cells are injected in the spleen, from where they rapidly 
migrate to the liver via the portal vein 296. 16 days after splenic injection, mice were 
euthanized and weights of tumor-bearing spleens and livers determined. Representative 
spleen and liver images are in Fig. 3.4A,E. Neither CDK8 knockdown (two shRNAs, Fig. 
3.4B,C) nor Senexin B treatment (Fig. 3.4D) had a significant effect on splenic tumor 
growth. In contrast, both CDK8 knockdown and Senexin B strongly decreased tumor 
growth in the liver, as indicated by liver weight (Fig. 3.4F-H) and histological 




FIGURE 3.4 Effects of CDK8 inhibition on CT26 murine colon cancer hepatic metastasis. 
Effects of CDK8 knockdown or inhibition on CT26 tumor growth in spleens and 
livers after splenic injection. 2x105 cells were injected into spleens (n=10) and the mice 
were euthanized 16 days after cell injection. (A, E) Representative images of tumor-
bearing spleens (A) or livers (E). (B,C,F,G) Effect of CDK8 knockdown (shCDK8-1 and 
shCDK8-2) relative to control cells (pLKO.1 and scramble) on tumor growth in spleens 
(B,C) or livers (F,G). Weights of tumor-bearing spleens and livers are shown.  Dotted lines 
indicate average weight of corresponding normal livers. P-values were determined by 
two-tailed t-test. (D, H) Effects of Senexin B on tumor growth in spleens (D) or livers (H). 
Senexin B (i.p., daily) or vehicle control (n=9) were administered from the day of injection. 
(I,K) Representative H&E staining of hepatic metastases from experiments in P and N, 
respectively. Scale bars: 2 mm. T: tumor. (J,L) Quantification of relative tumor area in the 
liver from experiments in P and N, respectively (n = 5).  
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To determine the effect of CDK8 inhibition on mouse survival of hepatic 
metastasis, spleens were removed 1 min after tumor inoculation. Mice, euthanized upon 
morbidity, showed extensive liver metastasis (Fig. 3.5A). Kaplan-Meier plots show that 
both CDK8 knockdown in tumor cells and systemic Senexin B treatment significantly 
affect survival, with the combination of CDK8 knockdown and Senexin B further 
increasing this effect (Fig. 3.5B). Figs. 3.5C,D show independent experiments confirming 
the effects of Senexin B treatment on the survival of mice injected intrasplenically with 
parental (Fig. 3.5C) or CDK8 knockdown CT26 (Fig. 3.5D). The effect of Senexin B was 
much stronger on parental than CDK8 knockdown cells.  
 
FIGURE 3.5. Effects of CDK8 inhibition on the survival of mice with hepatic metastasis. 
A: Representative macroscopic images of metastatic spread in mice from survival 
studies. Left: metastasis-containing liver in the abdominal cavity. Right: the abdominal 
cavity with liver removed. (B,C,D) Survival studies (Kaplan-Meier plots). Mice were 
injected with 2x105 cells into spleen and spleens were removed 1 min after inoculation. 
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Senexin B was administered from the day of inoculation. n = 10 in all experiments. 
Differences in mouse survival were evaluated by the log-rank test. (B) pLK0.1 control and 
shCDK8-1 cell lines, treated with vehicle or Senexin B (oral, b.i.d). (C) Parental CT26 cells 
treated with vehicle or Senexin B (diet + oral). (D) CT26-shCDK8-1 cells treated with 
vehicle or Senexin B as in (C).  
To determine if the effects of CDK8 inhibition on liver metastases were due to 
prevention of metastatic foci establishment or suppression of already established 
metastases, we asked whether CDK8/19 inhibition can affect tumor growth in the liver 
when the inhibitor is administered after establishment of metastases. Consistent with 
previously described  time to liver metastasis in this model 297, we found macroscopically 
and microscopically detectable metastases in 3/3 livers of mice 7 days after splenic 
inoculation (Fig. 3.6A), indicating that any effects after this point would involve 
suppression of hepatic tumor growth. We compared the effects of Senexin B 
administered (i) for two days prior to splenic inoculation, (ii) on days 1-7 (day 1 is the 
inoculation day), (iii) on days 8-14, or (iv) on days 1-14. The weights of tumor-bearing 
livers are in Fig. 3.6 B.  Senexin B administration prior to inoculation had no effect on liver 
metastasis. Drug administration on days 1-7 decreased liver weights although this effect 
did not reach statistical significance. On the other hand, treatments administered on days 
1-14 or 8-14 were efficacious in suppressing hepatic tumor growth, indicating that CDK8 
inhibition suppresses already-established liver metastases (Fig. 3.6B). This conclusion was 
confirmed by a survival study, where Senexin B administration initiated on day 8 after 
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splenic inoculation significantly extended mouse survival (Fig. 3.6C). 
 
FIGURE 3.6 Effects of CDK8 inhibition at different stages of liver metastatic growth. 
(A) Metastatic tumors in the livers of mice euthanized 7 days after splenic 
inoculation of CT26 cells, detectable macroscopically (upper left, tumor marked with 
arrow) and microscopically. Representative examples are shown. Scale bars: 0.2 mm. (B) 
Effects of Senexin B treatment at different stages of liver metastasis on tumor growth in 
liver. Mice (n=10) were treated with Senexin B (oral, b.i.d.) over two days prior to splenic 
inoculation, during the first week after inoculation, during the second week after 
inoculation, or over two weeks after inoculation of CT26 cells. Mice were euthanized two 
weeks after inoculation; liver weights are shown. (C) Mouse survival study conducted as 
in (Fig. 3.5 C) except drug treatment was started on day 8 after inoculation.  
Effects of CDK8 are mediated via TIMP3 and MMP3 expression.  
To understand the molecular mechanism of the effects of CDK8, a transcriptional 
regulator, on liver metastatic growth, we carried out transcriptomic analysis of the 
effects of CDK8 knockdown or Senexin B treatment in CT26 cells. Microarray 
hybridization revealed strong effects on several members of the matrix 
metalloproteinase (MMP) and tissue inhibitor of metalloproteinases (TIMP) families, 
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specifically TIMP3 that was upregulated and MMP3, MMP10 and MMP13 that were 
downregulated by CDK8 knockdown or inhibition (Fig. 3.7A-C), as validated by qPCR (Fig. 
3.7D). Senexin B mimicked the effects of CDK8 shRNA in control cells but not in cells with 
CDK8 knockdown (Fig. 3.7D).  
 
FIGURE 3.7 CDK8 regulates the expression of TIMP3 and MMPs. 
(A-C) Microarray analyses identify TIMP3, MMP3, MMP10 and MMP13 as CDK8 
targets in CT26 cells. (A) Illumina microarray comparing CT26-shCDK8-1 vs. CT26-pLKO.1. 
(B) Affymetrix microarray comparing CT26-shCDK8-2 vs. CT26-pLKO.1. (C) Affymetrix 
microarray comparing CT26 parental cells treated with DMSO or 1 µM Senexin B for 24 h. 
(D) qPCR analysis of the effects of CDK8 knockdown (shCDK8-1 and shCDK8-2) on the 
expression of TIMP3, MMP3, MMP10 and MMP13, in the absence or presence of Senexin 
B (1 M, 24 h treatment, in triplicates).  
The effects of Senexin B on gene expression were concentration and time 
dependent (Fig. 3.8A,C). Immunoblotting (Fig. 3.8B) confirmed concentration-dependent 
TIMP3 induction and MMP3 inhibition by Senexin B. CT26 tumors growing in the livers of 
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mice continuously treated with Senexin B also showed increased TIMP3 and decreased 
MMP3, MMP10 and MMP13 (Fig. 3.9A).  
 
 
FIGURE 3.8 TIMP3 or MMP3 expression analysis upon inhibition of CDK8 in vitro. 
(A) Concentration-dependent effect of Senexin B (24 h treatment) on TIMP3 or 
MMP3 expression (qPCR, in duplicates). (B) Effects of different Senexin B concentrations 
(24 hr treatment) on TIMP3 and MMP3 protein expression. (C) Effects of long-term 
treatment with 0.5 µM Senexin B for the indicated number of days on the expression of 
TIMP3, MMP3, MMP10 and MMP13 (qPCR, in duplicates). 
To determine if hepatic tumor growth is associated with altered CDK8, TIMP3 and 
MMP3 expression, we compared RNA expression of these genes between CT26 grown in 
culture or as tumors in spleen or liver. CDK8 was moderately elevated in splenic tumors 
relative to cells in culture but greatly elevated in hepatic tumors (Fig. 3.11A). TIMP3 was 
moderately increased in splenic tumors relative to cultured cells but decreased in hepatic 
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tumors. In contrast, MMP3 was increased to a similar degree in both splenic and hepatic 
tumors relative to cells in culture (Fig. 3.11A). We also analyzed transcriptomic data from 
tumors formed by the parental CT26 and their derivative CT26-FL3 selected in vivo for a 
high rate of hepatic metastasis following cecal implantation 299. Remarkably, CDK8 was 
significantly elevated and TIMP3 downregulated in highly metastatic relative to parental 
cells, whereas MMP3 elevation was not statistically significant (Fig. 3.11B).  
 
 
FIGURE 3.9 TIMP3 and MMPs expression analysis in vivo. 
(A) Effects of in vivo treatment with Senexin B on the expression of TIMP3, 
MMP3, MMP10, MMP13 and CDK8 in hepatic metastases. Mice (n=6) received vehicle or 
Senexin B (33 mg/kg, p.o., b.i.d.) starting from the day of splenic inoculation of CT26 cells 
for 14 days. (B) RNA expression of TIMP3, MMP3, MMP10, and MMP13 in subcutaneous 
CT26 tumors (n=3) or in the intestine (n=3). (C) Comparison of relative expression levels 






















FIGURE 3.10 Immunofluorescence analysis of timp3 and mmp3 in vivo. 
(A,B) Immunofluorescence analysis of the effects of in vivo treatment with Senexin B (diet 
+ oral) on days 11-14 after splenic inoculation on the expression of TIMP3 (A) and MMP3 




FIGURE 3.11 Metastasis related expression change of CDK8, TIMP3, MMP3. 
(A) Expression of CDK8, TIMP3 and MMP3 in CT26 cells growing in vitro or as 
tumors in spleen or in liver. Tumors were isolated from vehicle-treated mice (n= 3) 16 
days after splenic inoculation. (B) Expression of CDK8, TIMP3 and MMP3 in tumors 
derived from parental CT26 cells and their highly metastatic CT26-FL3 derivatives (data 
from GEO: GSE67675). 
 
To test the effect of TIMP3 on CT26 growth in the liver, we overexpressed human 
TIMP3 in CT26 cells (Fig. 3.12A,B). This overexpression had no effect on endogenous 
murine TIMP3 (Fig. 3.12B), CDK8 or MMP3 (Fig. 3.12C). TIMP3 overexpression did not 
affect cell growth in vitro (Fig. 3.13A) or in vivo, when injected s.c. (Fig. 3.13B,C) or in the 
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cecum (Fig. 3.13D,E). However, TIMP3 expression significantly increased mouse survival 
of liver metastasis in the splenic injection model (Fig. 3.13F). The effect of Senexin B 
treatment on mouse survival of tumors with TIMP3 overexpression (Fig. 3.13G) was much 
weaker than its effect on parental CT26 tumors (Fig. 3.5B,C) and similar to its effect on 
tumors with CDK8 knockdown (Fig. 3.5B,D). 
 
FIGURE 3.12 Overexpression of human TIMP3 in CT26 cells.  
(A) Expression of TIMP3 protein in CT26-VTIMP3 determined by immunoblotting. 
CT26-VGFP used as control. (B) Analysis of the overexpression of human TIMP3 in CT26-
VTIMP3 and control CT26-VGFP cells (qPCR, in duplicates). (C) Analysis of CDK8 and 
mouse TIMP3 expression in VTIMP3 and VGFP cells (qPCR, in duplicates). 
MMP3 knockdown (Fig. 3.14A,B) had no significant effect on CDK8 or TIMP3 
expression (Fig. 3.14C,D), cell growth in vitro (Fig. 3.15A) or tumor growth s.c. (Fig. 
3.15B,C) but strongly increased mouse survival in the splenic injection model (Fig. 3.15D) 
and lessened the survival effect of Senexin B (Fig. 3.15E). These results identify TIMP3 
upregulation and MMP3 downregulation as events mediating the suppression of hepatic 





FIGURE 3.13. Effects of overexpression of TIMP3 on CT26 cells in vitro and in vivo.  
(A) Dynamics of cell growth of VTIMP3 and VGFP cells in vitro. (B) Dynamics of 
VTIMP3 and VGFP tumor growth and (C) final tumor volumes of VTIMP3 and VGFP 
derivatives injected s.c. (n=10). (D) Images of representative orthotopic tumors formed by 
VTIMP3 and VGFP cells after cecal injection. (E) Weights of orthotopic VTIMP3 and VGFP 
tumors (30 days after cecal injection) relative to VGFP (control) (n=10). (F) Kaplan-Meier 
survival plots of mice following splenic injection of VTIMP3 and VGFP cells. (G). Kaplan-
Meier survival plots of mice following splenic injection with VTIMP3 cells and treatment 
with vehicle or Senexin B. Survival studies and Senexin B treatment were conducted as in 





FIGURE 3.14 Knockdown of MMP3 in CT26 cells. 
(A) Immunoblotting analysis of MMP3 protein knockdown with different shRNAs. 
(B) Analysis of MMP3 knockdown by five different shRNAs. (C) qPCR analysis of CDK8 and 
TIMP3 expression in MMP3 knockdown cells (qPCR, in duplicates). 
 
CDK8 regulates TIMP3 and MMP3 expression and hepatic metastasis through 
effects on TGFβ/SMAD-regulated miR-181b expression and the Wnt/β-catenin 
pathway.  
TIMP3 can be regulated by TGFβ/SMAD both positively 300 and negatively, via 
SMAD-dependent microRNA expression 301,302. Importantly, SMAD activity is potentiated 
by CDK8 228,303. To examine the role of TGFβ/SMAD in TIMP3 regulation by CDK8, we 
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knocked down SMAD4, the common mediator of R-SMAD transcription factors 304 (Fig. 
3.16A,B). SMAD4 knockdown had no significant effect on cell growth in vitro (Fig. 3.16C). 
While CDK8 inhibition had no effect on SMAD4 expression (Fig. 3.16A), SMAD4 
knockdown, like CDK8 inhibition, induced TIMP3 both at RNA (Fig. 3.16A) and protein 
levels (Fig. 3.16B). The relative effect of Senexin B on TIMP3 was greatly diminished by 
SMAD4 knockdown and the relative effect of SMAD4 knockdown was similarly reduced 
by Senexin B (Fig. 3.16A). On the other hand, SMAD4 knockdown, in contrast to CDK8 
inhibition, appeared to induce rather than inhibit MMP3 expression and did not interfere 
with MMP3 inhibition by Senexin B (Fig. 3.16A). These results indicate that the effect of 
CDK8 on TGFβ/SMAD mediates to a large extent the effect of CDK8 on TIMP3 (but not 
MMP3) transcription. 
 
FIGURE 3.15 Effects of overexpression of TIMP3 on CT26 cells in vitro and in vivo. 
(A) Effect of MMP3 knockdown on CT26 cell growth in vitro (n = 10) (B) Effect of 
MMP3 knockdown on the dynamics of CT26 tumor growth s.c. (n = 10). (C) Final tumor 
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volumes of control and MMP3 knockdown derivatives injected s.c. (n=10). (D) Kaplan-
Meier survival plots of mice following splenic injection of control and MMP3 knockdown 
cells. (E). Kaplan-Meier survival plots of mice following splenic injection with MMP3 
knockdown cells and treatment with vehicle or Senexin B. Mouse survival studies and 
Senexin B treatment were conducted as in in Fig. 3.5 B. 
 
FIGURE 3.16 Knockdown of SMAD4 in CT26 cells. 
(A) Effects of SMAD4 knockdown by two different shRNAs on the expression of 
SMAD4, TIMP3 and MMP3 in the absence or presence of 1 μM Senexin B (24 hr 
treatment), (qPCR, in duplicates). (B) Effects of SMAD4 knockdown on the expression of 
SMAD4, TIMP3 by western blotting. (C) Effects of SMAD4 knockdown on the growth of 
CT26 cells.  
Since TIMP3 was reported to be inhibited by several microRNAs including 
TGFβ/SMAD-regulated miR-181b, as well as miR-21a, miR-21b, miR-125b1, miR-125b2 
and miR-712 305-307, we measured the effects of Senexin B and CDK8 or SMAD4 
79 
 
knockdown on the expression of these microRNAs. While most microRNAs were 
unaffected by CDK8 inhibition (Fig. 3.17), Senexin B and CDK8 or SMAD4 knockdown 
decreased miR-181b levels. The relative effect of Senexin B was greatly decreased in 
CDK8 or SMAD4 knockdown cells (Fig. 3.17). A mimic of miR-181b transfected into 
parental CT26 cells prevented TIMP3 induction upon treatment with Senexin B or by 
CDK8 or SMAD4 knockdown compared to control cells (Fig. 3.18A,B). Conversely, 
transfection of miR-181b antagonist into parental CT26 strongly induced TIMP3 
expression, with a much weaker effect in cells with CDK8 or SMAD4 knockdown (Fig. 
3.18C). These results indicate that CDK8 inhibition induces TIMP3 via SMAD-regulated 
expression of miR-181b. Notably, while CDK8 regulated miR-181b (Fig. 3.17), miR-181b or 
its antagonist had no effect on CDK8 expression (Fig. 3.18B,C).  
 
FIGURE 3.17 Effect of CDK8 or SMAD4 knockdown on the expression of miRNAs.  
Expression of the indicated microRNAs in CT26- pLKO.1, CT26-shCDK8 or CT26-






FIGURE 3.18 The effect of miRNA181b on the expression of TIMP3. 
(A) Expression of TIMP3 in CT26 cells transfected with control miRNA mimic or 
miR-181b mimic, in the absence or presence of 1 µM Senexin B (qPCR, in duplicates) for 
18 h (Senexin B treatment started 8 h after transfection). (B) Expression of TIMP3 and 
CDK8 in CT26-pLKO.1, CT26-shCDK8 and CT26-shSMAD4 cells transfected with control 
miRNA mimic or miR-181b mimic (qPCR, in duplicates). (C) Expression of TIMP3 and CDK8 
in CT26-pLKO.1, CT26-shCDK8 and CT26-shSMAD4 cells transfected with control miRNA 
mimic or miR-181b inhibitor (qPCR, in duplicates). 
Several MMPs, including MMP3, are known transcriptional targets of wnt/β-
catenin 308, which is regulated by CDK8 286. To determine if the effect of CDK8 on MMP3 
could be mediated through wnt/β-catenin, we generated -catenin (CTNNB1) knockdown 
derivatives of CT26 (Fig. 3.19A). CTNNB1 knockdown had no significant effect on cell 
growth in vitro (Fig. 3.19E). Senexin B did not affect CTNNB1 expression (Fig. 3.19B) but 
CTNNB1 knockdown mimicked CDK8 inhibition by downregulating MMP3 at both RNA 
(Fig. 3.19B) and protein levels (Fig. 3.19D). The relative effect of Senexin B on MMP3 was 
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greatly diminished upon CTNNB1 knockdown and the relative effect of CTNNB1 
knockdown was similarly reduced by Senexin B (Fig. 3.19D). In addition to the strong 
effect on MMP3, CTNNB1 knockdown moderately induced TIMP3 and showed a modest 
effect on TIMP3 induction by Senexin B (Fig. 3.19C). These results suggest that the 
Wnt/β-catenin pathway mediates to a large extent the effect of CDK8 on MMP3 and to a 
lesser extent on TIMP3. 
 
FIGURE 3.19 Knockdown of β-catenin in CT26 cells. 
(A-C) Effects of CTNNB1 knockdown (A) by two different shRNAs on the expression 
of MMP3 (B) and TIMP3 (C) in CT26 cells, in the absence or presence of 1 μM Senexin B 
(24 hr treatment) (qPCR, in duplicates). (D) The effect of knockdown of CTNNB1 on the 





We have also tested if STAT1, another pleiotropic transcription factor known to 
be co-regulated by CDK8 292, is involved in TIMP3 and MMP3 regulation. While Senexin B 
inhibited STAT1 phosphorylation at S727 (Fig. 3.20A), STAT1 knockdown had no effect on 
TIMP3 or MMP3 expression (Fig. 3.20B).  
 
FIGURE 3.20 Effect of knockdown of STAT1 on TIMP3 and MMP3 in CT26 cells. 
(A) STAT1 knockdown by two different shRNAs in CT26 cells (immunoblotting). (B) 
Expression of MMP3 and TIMP3 in CT26 cells with STAT1 knockdown (qPCR, in 
duplicates).  
We compared the effects of the knockdowns of CDK8, SMAD4 and CTNNB1 on 
tumor growth in vivo, using s.c. and splenic injection models. CTNNB1 knockdown 
significantly inhibited tumor growth s.c. (Fig. 3.21A) and strongly inhibited tumor growth 
in the spleen (Fig. 3.21B), whereas neither CDK8 nor SMAD4 knockdown had significant 
effects at these sites (Fig. 3.21A,B). In contrast, hepatic tumor growth was significantly 
suppressed by CDK8, CTNNB1 or SMAD4 knockdown (Fig. 3.21C). Hence, both 
TGFβ/SMAD and Wnt/β-catenin pathways regulate the growth of hepatic metastases in 





FIGURE 3.21 Effect of the knockdown of cdk8, ctnnb-1 and smad4 on CT26 cells in 
vivo. 
(A) Effects of CDK8, CTNNB1 and SMAD4 knockdown on the growth of CT26 s.c. 
tumors. 106 cells were injected s.c. and tumor weights were measured after 16 days. 
CT26-pLKO.1 cells were used as control (n=10).  (B, C) Effects of CDK8, CTNNB1 and 
SMAD4 knockdown on CT26 growth in spleen (B) and liver (C) after splenic injection of 
2x105 cells. Mice (n=10) were euthanized 16 days after injection. 
CDK8 inhibition induces TIMP3, inhibits MMP9 and suppresses hepatic metastasis in 
human colon cancer cells.  
The effects of Senexin B on TIMP3 and different MMPs were analyzed in a panel 
of 10 human colon cancer cell lines. Senexin B induced TIMP3 expression, with 
statistically significant induction in 7 of 10 lines (Fig. 3.22). Among the MMPs, MMP9 was 
inhibited by Senexin B in most cell lines (Fig. 3.22), whereas MMP3, MMP10, MMP13, 
MMP2 and MMP7 were not significantly affected by the inhibitor (Fig. 3.22). Inducible 
expression of CDK8 shRNA in HCT116 cells also induced TIMP3 and inhibited MMP9, 




FIGURE 3.22. Effects of Senexin B on TIMP3 and MMPs in colon cancer cell lines.  
Effects of Senexin B on the expression of different MMPs and TIMP3 in a panel of 
human colon cancer cell lines. qPCR analysis of the effects of 1 µM Senexin B (24 h 
treatment) on the expression of the indicated MMPs in the indicated cell lines (qPCR, in 
duplicates). 
 
FIGURE 3.23. Effect of knockdown of CDK8 on the expression of TIMP3 and MMP9. 
(A,B) qPCR analysis of the effects of doxycycline-inducible CDK8 shRNA on TIMP3 
(A) and MMP3 (B) expression in HCT116 cells. Cells were treated with 1 M doxycycline or 
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vehicle control for 72 hrs, Senexin B was added where indicated for the last 24 h of this 
treatment (all qPCR in duplicates). 
We analyzed the effect of Senexin B on liver metastatic growth of human HCT116 
cells in nude mice (Fig. 3.24B-E). Following splenic injection and spleen resection, mice 
were treated with Senexin B or vehicle control. 7 weeks after tumor inoculation, mice 
were euthanized and livers, all of which contained tumor metastases (Fig. 3.24B), were 
weighed. Analysis of liver weights (Fig. 3.24C) and tumor areas in the liver (Fig. 3.24D,E) 
showed strong inhibition of hepatic tumor growth by Senexin B. Notably, even the long 
(7-week) Senexin B treatment showed no apparent toxicity (mouse body weights over 
the course of the study increased by 9.4±1.3% in the control group and by 7.1±1.4% in 
the Senexin B-treated group). In contrast to its effect on tumor growth in the liver, 
Senexin B did not inhibit the growth of HCT116 tumors s.c. (Fig. 3.24A). 
 
FIGURE 3.24. The effect of CDK8 inhibition on the tumor growth of HCT116 cells in vivo.  
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(A) Dynamics of HCT116 tumor growth s.c. in mice treated with Senexin B (33 
mg/kg, p.o., b.i.d) or vehicle control (n = 5). (B-E) Effect of Senexin B on HCT116 hepatic 
metastasis. 106 HCT116 cells were injected into spleens and spleens were removed 1 min 
after injection. Vehicle or Senexin B (oral, b.i.d., 5 days a week) (n=9) were administered 
from the day of injection for a period of 6 weeks. B: Representative images of HCT116 
tumor-bearing livers in mice treated with vehicle or Senexin B. C: Weights of tumor-
bearing livers. D: Representative H&E staining of hepatic metastases. T: tumor. Scale 
bars: 1 mm. E: quantitation of relative tumor areas in the liver (n = 4). 
Discussion 
Mediator kinase CDK8 was first identified as an oncogene in colon cancer, where 
CDK8 was found to be amplified in a sizable subset of tumors and to act as a positive 
mediator of the Wnt/β-catenin pathway that plays a key role in colon carcinogenesis 286. 
High CDK8 expression has been established as a negative prognostic marker in colon 
cancer 287. Our analysis of the RNA-Seq database confirms this association and shows that 
not only CDK8 but also CDK19 and their interactive proteins MED13 and MED13L are 
expressed at a higher level in high-risk colon cancers, although CDK8 shows the strongest 
correlations. CDK8 shRNA was reported to inhibit the proliferation of CDK8-
overexpressing colon cancer cells in vitro 286 and in vivo 309,310 but a variety of CDK8/19 
kinase inhibitors failed to suppress the growth of colon cancers in vitro or in primary 
tumors 288-290.  (A moderate but significant effect on the proliferation and primary 
xenograft growth of a small subset of colon cancer cell lines was observed with CDK8/19 
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inhibitors that also showed a pronounced toxicity 206. However, transcriptomic analysis of 
in vivo effects of these inhibitors indicated pleiotropic effects that were very different 
from pathway-specific effects of another CDK8/19 targeting agent 224 suggesting possible 
off-target activities.) In the present study, we tested three human colon cancer cell lines 
(HCT116, HT29 and SW480)  with CDK8 amplification or overexpression for the effect of 
Senexin B, an early-stage clinical drug candidate which is highly selective for CDK8 and its 
paralog CDK19 291, on cell proliferation. CDK8 kinase inhibition or inducible shRNA 
knockdown in 2 of 3 cell lines was not associated with any effects on cell proliferation in a 
5-day assay or on the number of colonies formed by these cells. However, in the third cell 
line (SW480), CDK8 kinase inhibition had a notable effect on colony formation but not on 
short-term cell growth. These results suggest that oncogenic effects of CDK8 in colon 
cancer are not generally mediated by the effects of CDK8 on cell proliferation.  
The different effects of CDK8 on long-term colony formation in different cell lines 
might due to the distribution of β-catenin.  HCT116 cells are heterozygous for β-catenin 
mutation that renders it resistant to degradation and these cells are believed to be β-
catenin dependent 217. HT29 and SW480 are wild-type for β-catenin but harbor APC 
mutation, which slows down β-catenin degradation311. However, under the normal 
culture conditions, the bulk of β-catenin is located in the cytoplasm in HCT116 and HT29 
cells while in SW480 cells, most of the β-catenin stays in the nucleus 218-220. In 
concordance with this, our data showed that inhibition of CDK8 with Senexin B had 
limited effect on the colony formation of HCT116 and HT29 cells but significant inhibitory 
effect was observed on SW480 cells.  
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To determine if CDK8 inhibition could have an in vivo therapeutic effect on colon 
cancer cells that do not respond to such inhibition in vitro, we have investigated the 
effects of CDK8 knockdown or kinase inhibition on the growth of CT26 tumors implanted 
at different sites and on liver metastases arising after splenic injection. We found that 
CDK8 inhibition had no significant effect on the growth of colon cancer cells implanted 
s.c., into the spleen or orthotopically into the cecum. However, both CDK8 knockdown in 
tumor cells and treatment of mice with the CDK8 kinase inhibitor strongly suppressed 
metastatic tumor growth in the liver. In accordance with the selective effect of CDK8 
inhibition on tumor growth in the liver, CDK8 expression was selectively elevated in CT26 
tumors growing in the liver and in a subline of CT26 cells selected for increased 
propensity for liver metastasis46. While most of our in vivo studies were conducted in a 
syngeneic mouse model, we have confirmed that the growth of hepatic metastases was 
suppressed by the CDK8 inhibitor in CDK8-overexpressing human HCT116 cells, where 
the inhibitor did not suppress cell growth in culture or in s.c. xenografts. Remarkably, a 
recent study comparing the copy number profiles of paired primary and liver metastatic 
samples from colon cancer patients identified CDK8 as one of the few genes that showed 
selective gene amplification in liver metastasis relative to primary tumor 230, in 
concordance with our results. The effects of the CDK8/19 inhibitor on metastatic growth 
in the liver were associated with no apparent toxicity and no loss in mouse body weights 
relative to the control. Importantly, suppression of liver metastasis by CDK8 inhibition 
was exerted at least in part through the inhibition of tumor growth in the liver rather 
than initial liver colonization, as indicated by the effects of treatment that was started 
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after the establishment of liver metastases (one week after inoculation). Many anticancer 
drug candidates show great efficacy in primary tumor models but are inefficient in 
preclinical models of metastatic disease, providing a plausible explanation for the failure 
of such agents in clinical trials of metastatic cancer 312. Our results reveal CDK8/19 
inhibitors as a remarkable exception to this rule, which are active against the metastatic 
disease even when inefficient against the primary tumors. 
Since CDK8 is a nuclear protein that has no known functions other than 
transcriptional regulation, we have used transcriptomic analysis to elucidate the 
mechanism of the anti-metastatic effects of CDK8 inhibition. Strikingly, one of the genes 
that was most strongly induced by CDK8 knockdown or Senexin B was TIMP3 and three of 
the most strongly inhibited genes were MMPs. The effects of CDK8 inhibition on the 
expression of TIMP3 and the MMPs were observed both in vitro and in vivo, in murine 
and human models. The network of MMPs and TIMPs (the natural MMP inhibitors) plays 
a major role in tumor progression in different cancers, including colon cancer, and it has 
long been considered an area for therapeutic intervention. MMPs and TIMPs are now 
understood to play key roles in a variety of biological processes aside from their best-
known role in matrix degradation, including growth factor receptor signaling, regulation 
of angiogenesis, apoptosis and cancers 313,314 . 
We have found that CDK8 inhibition in murine CT26 cells downregulates MMP3, 
which is highly expressed in mouse CT26 cells, as well as MMP10 and MMP13, which are 
expressed at much lower levels. CDK8 inhibition in a panel of human colon cancer cell 
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lines suppressed the expression of another metastasis-associated MMP, MMP9; 
remarkably, MMP3 acts as a proteolytic activator of MMP9 315. These results indicate that 
CDK8 affects the expression of specific metastasis-associated MMPs in colon cancer cells. 
MMP3 knockdown strongly increased the mouse survival of liver metastasis and 
diminished the relative anti-metastatic effect of CDK8 inhibition in CT26 cells, providing, 
to the best of our knowledge, the first demonstration of a functional role of MMP3 in 
colon cancer metastasis. CTNNB1 knockdown studies showed that CDK8 regulates MMP3 
expression to a large extent through its effect on the wnt/β-catenin pathway. This 
pathway was previously shown to be co-regulated by CDK8 in vitro 286,316 but to the best 
of our knowledge, the present study provides the first example of an in vivo effect of 
CDK8/19 kinase inhibitors on the wnt/β-catenin pathway.  
Among CDK8-regulated genes, TIMP3 has been identified as a suppressor of 
invasion, metastasis and angiogenesis in different types of cancer, including colorectal 
cancers 298. TIMP3 inhibits both MMPs and a related ADAM protease family, which are 
essential for angiogenesis and required for the dissemination and establishment of tumor 
metastases317. Protease-mediated degradation of extracellular matrix (ECM) and capillary 
basement membrane, provides not only the space for angiogenesis but also the tethered 
growth factors, such as vascular endothelial growth factor (VEGF), are released from 
ECM, which further promotes the secretion of MMPs, forming a positive feedback to 
expand the angiogenesis process318. In support of the role in angiogenesis, TIMP3 
expression was inversely correlated with the vessel density in the tumors of melanoma 
patients319. TIMP3 also showed MMP-independent activity to inhibit VEGF-mediated 
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angiogenesis by directly interrupting the binding between VEGF receptor-2 and VEGF and 
blocking the downstream signaling pathway320,321.  TIMP3 could also directly induce 
apoptosis in epithelial cells322. TIMP3 has been demonstrated by several groups to play 
important roles in colon cancer metastasis. With paired primary and liver metastatic 
colorectal samples, genome-wide methylation analysis found that methylation 
frequencies of TIMP3 increased gradually from stage I-III to liver metastasis323. 
Consistently with this finding, another group discovered that the protein levels of TIMP3 
were negatively related to staging in colon carcinoma, with the lowest expression in the 
samples with lymph node metastasis324. Adenovirus mediated expression of TIMP3 in 
CT26 cells, one of the mostly used colon cancer cell lines for metastasis studies, 
significantly decreased both the size and the number of metastatic tumors in the liver325. 
Also in human HCT116 colon cancer cell line, IncRNA BC032913 significantly inhibited 
both lung and liver metastasis by upregulating TIMP3 expression326. 
Induction of TIMP3 was the most consistent metastasis-relevant transcriptional 
effect of CDK8 inhibition observed in all the tested murine and human colon cancer cell 
lines. Furthermore, TIMP3 was induced even by the lowest tested concentrations of 
Senexin B that showed no detectable effect on MMP expression. Both liver-derived 
tumors and a CT26 derivative selected for increased propensity for liver metastasis 299 
showed concurrent upregulation of CDK8 and downregulation of TIMP3. Furthermore, 
TIMP3 overexpression, like CDK8 inhibition, had no significant effect on primary tumor 
growth but increased mouse survival of liver metastatic disease and reduced the relative 
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effect of Senexin B on liver metastasis. These results suggest that TIMP3 is the primary 
and most general mediator of the effects of CDK8 on tumor growth in the liver.   
Notably, the later stages of liver metastatic growth require angiogenesis (which is 
suppressed by TIMP3) and involve deposition of fibrosis-like matrix (susceptible to 
proteinases) that restrains metastases. The growth of metastatic tumors could trigger a 
response resembling wound healing in the liver, which causes deposition of fibrosis like 
matrix to increase the "tightness" of tumor microenvironment and restrain the growth of 
metastases. In the CT26 liver metastasis experiments, alpha-SMA, a reliable predicator 
for fibrous tissue deposition327, showed positive staining at the edge between hepatic 
tissue and metastatic tumors. The MMPs and other ECM-degrading proteinases are of 
critical importance for metastatic tumor growth in the liver52. In fact, the divergent 
effects of inhibition of CDK8 on the growth of the primary tumors and the metastatic 
tumors in liver could be partially explained by the "tightness" theory. The primary tumor, 
implanted s.c. or in the spleen or orthotopically, usually grows to a large size and has less 
of the surface area relative to volume as compared to the metastatic tumor in liver and 
also has relatively less fibrosis-like matrix to deal with. Consequently, the growth of 
primary tumor is less affected by MMPs/TIMPs balance, while the metastatic tumor has 
to expand its growth space by ECM-degrading proteinases, which are inhibited by TIMP3.  
Regulation of TIMP3 by CDK8 was found to be mediated via the TGF-β/SMAD 
pathway. The TGF-β/SMAD pathway was shown to be potentiated by CDK8 through 
SMAD phosphorylation, which stimulates SMAD-driven transcription but also promotes 
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the eventual degradation of SMADs 303. TGF-β/SMAD-regulated TIMP3 expression in 
other cell types was found to be mediated via SMAD-responsive transcription of miR-
181b that directly targets TIMP3 301,302.  We have found that miR-181b negatively 
regulates TIMP3 expression in colon cancer cells and that CDK8 inhibition suppresses 
miR-181b expression via the effects of CDK8 on SMAD-driven transcription. While there 
are reports of microRNAs that regulate CDK8 expression, to the best of our knowledge, 
this is the first example of a microRNA regulated by CDK8 and mediating its biological 
activity. The mechanisms of positive regulation of transcription by CDK8 have been 
elucidated in many cases 207,213,293,328. However, such is not the case for negative 
regulation of gene expression by CDK8 in mammalian cells, where the only reported 
mechanism was accelerated degradation of CDK8-phosphorylated transcription factors 
329. Our findings raise the possibility that positive regulation of microRNAs could be an 
important mechanism for negative regulation of gene expression by CDK8. 
BMP-4, a member of the TGF-β/BMP family, is universally upregulated in colon 
cancer cells and tissues 330 indicating that the TGF-β/SMAD pathway is commonly 
activated in colon cancers. This pathway has been implicated in the metastatic 
phenotype of a subset of colon cancers 331 and our data demonstrate that SMAD4 
knockdown in the CT26 model selectively inhibits hepatic metastasis, while having no 
effect on cell growth in vitro or primary tumor growth. The effects of SMAD4 and CDK8 
knockdowns (or CDK8/19 kinase inhibition) were remarkably similar, both qualitatively 
and quantitatively (much more similar than the effects of CDK8 and -catenin 
knockdown), which, together with the data for the role of TGF-β/SMAD in CDK8-
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regulated TIMP3 expression, identifies CDK8/19 as a promising druggable mediator of the 
in vivo tumor-promoting effects of the TGF-β/SMAD pathway. 
Both CDK8 knockdown in tumor cells and systemic treatment of animals with 
CDK8 kinase inhibitor strongly suppressed colon cancer hepatic metastasis but had no 
significant effect on primary tumor growth. These similarities indicate that the role of 
CDK8 in colon cancer metastasis is at least in part cell-autonomous. However, we also 
saw that treatment of animals with Senexin B had a much weaker but still significant 
effect on hepatic metastasis of tumors with CDK8 knockdown. While we cannot exclude 
that this effect is due to the low levels of CDK8 (or CDK19) remaining in the knockdown 
cells, the most apparent interpretation of this result is that a part of the anti-metastatic 
effect of the CDK8 inhibitor is non-cell-autonomous and is exerted through the effects of 
CDK8/19 inhibition on the tumor microenvironment or the immune system. As a 
plausible mechanism, CDK8 was reported to be a negative mediator of tumor surveillance 
activities of natural killer (NK) cells, and CDK8 knockdown increased such activities 332. 
Such potential effects of CDK8 on the stromal microenvironment will be investigated in 
future studies. 
The mechanism of the potentiation of hepatic metastasis by CDK8, via the 
regulation of MMP and TIMP3 expression, is summarized in Fig. 3.25. CDK8 potentiates 
MMP expression primarily through its effects on /wnt/β-catenin mediated transcription. 
At the same time, CDK8, through its potentiating effect on the TGF-β/SMAD pathway, 
stimulates the expression of miR-181b, which suppresses TIMP3 expression. Inhibition of 
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CDK8 suppresses the expression of both MMPs and miR-181b, allowing the expression of 
TIMP3. TIMP3 production inhibits a broad spectrum of MMPs, suppressing metastatic 
growth of colon cancer cells in the liver. Given the major contribution of hepatic 
metastasis to colon cancer mortality, the metastasis-suppressing effects of CDK8 
inhibition warrant exploring the use of CDK8-targeting drugs for the treatment of hepatic 
metastasis of colon cancer. Furthermore, CDK8 inhibitors may potentially be useful in 
other therapeutic settings that involve TGF-β/SMAD and wnt/β-catenin pathways.  
 
FIGURE 3.25. The effects of CDK8 inhibition on metastatic tumor growth liver. 
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in colon cancer cells inhibits TIMP3 and activates matrix metalloproteinases gene 









 MATERIALS AND METHODS 
(all the reagents and resources can be found in Table.4.1) 
TABLE 4.1 Key reagents and resources 
REAGENT or RESOURCE SOURCE IDENTIFIER or SEQUENCE 
Antibodies 
Anti-CDK8 SantaCruz Cat#sc-1521 
Anti-CDK19 Sigma Cat#HPA007053 
Anti-SMAD4 Cell Signaling Cat#9515s 
Anti-β-Catenin Cell Signaling Cat#9587s 




Anti-β-Actin Cell Signaling Cat#3700 
HRP-anti-goat IgG  SantaCruz Cat#sc-2020 
HRP-anti-rabbit IgG ThermoFisher 
Scientific 
Cat#31460 
HRP-anti-mouse IgG ThermoFisher 
Scientific 
Cat#31430 
Alexa Fluor® 488-anti-rabbit IgG ThermoFisher 
Scientific 
Cat#A-21206 
Alexa Fluor® 594-anti-rabbit IgG ThermoFisher 
Scientific 
Cat#A-21203 
Bacterial and Virus Strains  





Chemicals, Peptides, and Recombinant Proteins 
Senexin B Senex Biotechnology   




RNeasy Mini Kit Qiagen Cat#74106 
iScript cDNA synthesis kit Bio-Rad Laboratories  Cat#1708891 
98 
 
iTaqTM Universal SYBR® Green 
Supermix 
Bio-Rad Laboratories Cat#172-5124 
QiaQuick Gel Extraction Kit  Qiagen Cat#28706 
CloneDirect™ Rapid Ligation Kit Lucigen Cat#40020 
Lipofectamine™ 3000 ThermoFisher 
Scientific 
Cat#L3000015 
SureBeads Protein G Mag beads Bio-Rad Laboratories Cat#1614023 
DC Protein Assay Kit Bio-Rad Laboratories Cat#5000116 
E. coli Poly(A) Polymerase New England BioLabs Cat#M0276 
Tetro Reverse Transcriptase kit Bioline Cat#BIO-65050 
RNA picochip and reagents, 
Bioanalyzer 2100 
  
DNA 7500 chip and reagents, 
Bioanalyzer 2100 
  
Experimental Models: Cell Lines 
CT26 ATCC CRL2638 
HCT-116 ATCC CRL-247 
LoVo ATCC CRL-229 
SW620 ATCC CRL-227 
SW480 ATCC CRL-228 
SW948 ATCC CRL-237 
SW48 ATCC CRL-231 
DLD-1 ATCC CCL-221 
HT-29 ATCC HTB-38 
SW116 ATCC CCL-233 




Experimental Models: Organisms/Strains 
Mouse: BALB/cJ The Jackson 
Laboratory 
Stock No: 000651 
Mouse: Athymic nude (nu/nu) The Jackson 
Laboratory 
Stock No: 002019 










pLenti6-TR Thermo Fisher 
Scientific 
Cat# V48020 
pRK5M-TIMP3 Addgene Plasmid #31715 
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Tet-pLKO-puro Addgene Plasmid #21915 
shCDK8-1 Sigma-Aldrich TRCN0000322327 
shCDK8-2 Sigma-Aldrich TRCN0000322410 
shCDK19-1 Sigma-Aldrich TRCN0000023283 
shCDK19-2 Sigma-Aldrich TRCN0000360760 
shMMP3-1 Sigma-Aldrich TRCN0000031237 
shMMP3-2 Sigma-Aldrich TRCN0000348486 
shMMP3-3 Sigma-Aldrich TRCN000031234 
shSMAD4-1 Sigma-Aldrich TRCN0000025885 
shSMAD4-2 Sigma-Aldrich TRCN0000025900  
shSMAD4-3 Sigma-Aldrich TRCN0000362660 
shSTAT1-1 Sigma-Aldrich TRCN0000054924 
shSTAT1-2 Sigma-Aldrich TRCN0000054926  
shCTNNB1-1 Sigma-Aldrich TRCN0000012688 
shCTNNB1-2 Sigma-Aldrich TRCN0000012692 
human shCDK8  This paper GCTTCCAAGTTGTACCTAT
TT 
Mmu-miR-181-5p-mimic Dharmacon C-310587-07-0002 
miRIDIAN microRNA mmu-miR-
181b-5p hairpin inhibitor 
Dharmacon IH-310587-08-0002 
Mimic negative control #1 Dharmacon CN-001000-01-05 
Software and Algorithms 
GraphPad Prism 5  GraphPad Software Prism 5 
SurvExpress 
For the Kaplan-Meier study with 
clinical data 





Microarray data analysis Thermo Fisher 
Scientific 
Expression Console 




Cell Lines and culture 
CT26 mouse colon cancer cells were a gift from Dr. Maria Marjorette (Marj) Pena 
(University of South Carolina, Columbia, SC), HCT116, Lovo, SW480, SW620, DLD-1, 
SW948 and HEK293-FT cells were obtained from American Type Culture Collection (ATCC, 
Manassas, VA). CT26 cells were maintained in RPMI-1640 (ThermoFisher Scientific, 
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Waltham, MA, USA) with 10% fetal bovine serum (FBS) (Atlanta Biologics, Flowery 
Branch, GA, USA), 1% penicillin-streptomycin and 2mM L-glutamine (VWR, Radnor, PA, 
USA). HCT116, Lovo, SW480, SW620, DLD-1, SW948 and HEK293-FT cells were 
maintained in DMEM-high glucose media (Thermo Fisher Scientific) with 10% FBS, 1% 
penicillin-streptomycin and 2 mM L-glutamine. All cell lines were routinely confirmed to 
be free of Mycoplasma (MycoAlert PLUS mycoplasma detection kit (Lonza, Walkersville, 
MD, USA).  Senexin B and Senexin B dimaleate were from Senex Biotechnology 
(Columbia, SC, USA). 
Cell passage 
Usually, 1 million cells were grown as adherent monolayers in VWR® Tissue 
Culture Dishes 100 mm, in 5% CO2 at 37°C. Cells were split when they reached 80-90% 
confluence. Briefly, media was aspirated from the culture dish. Cells were rinsed with PBS 
to remove residual serum; 4 ml trypsin, (trypsin 0.05% w/EDTA) (Thermo Fisher Scientific) 
was added onto the cells and shaken back and forth for a while and then aspirated. The 
cells were incubated in the incubator for detachment. It usually took 3-5 min to complete 
this process and check under the microscope if necessary. Once cells had detached, 
trypsin was inactivated by the addition of 10 ml medium containing serum.  The cells in 
the medium were thoroughly pipetted to obtain single cell suspension. The suspension of 
cells was applied for cell counting. Briefly, 10 μl cell suspension was added into cell 
counter slides (Bio-Rad) and then analyzed by the TC10 Automated Cell Counter (Bio-






Freezing media was prepared by mix 10% dimethyl sulphoxide (DMSO; Sigma 
Aldrich) and 90% FBS. Cells were detached with trypsin as described before. 10 million of 
cells were spin down at 250 g for 5 minutes. The pelleted cells were suspended in 10 ml 
freezing media on ice. Aliquots at 1 ml were transferred to labelled cryovials (WHEATON 
CryoELITE, VWR) and frozen at -80°C overnight. The frozen cells can be kept at -80°C for 
months and kept in liquid nitrogen for years.  
Cell recovery 
The frozen cells can be recovered for cell culture by thawing process. The frozen 
cells were put on dry ice and brought to the tissue culture room. 10 ml pre-warmed cell 
growth medium was added into p100 dish. Cells were thawed in the thermostatic bath 
set at 37 °C and transferred to the growth medium immediately when the ice thawed. 
Cells were kept in the incubator overnight. The medium with DMSO and dead cells was 
changed with fresh growth medium next day. 
In vitro cell growth test 
For in vitro cell growth test, 1 x 10^5 cells were seeded into p100 dish with the 
corresponding cell culture medium. Senexin B or DMSO at indicated concentration was 
added to culture medium at the same time. Cell numbers were recorded every day until 




p100 plate was coated with 25 μg/ml of PEI at final concentration for 5 min late 
and rinsed twice with PBS. 1000 single cell suspension were seeded into the coated plate 
w/o Senexin B at 1 μM. Culture medium was aspirated when the diameter of colony was 
around 1 mm. The colony was washed once with PBS and treated with 4% formaldehyde 
for 10 min and rinsed with PBS one time. Colonies were stained with 0.25% R250 
Coomassie bright blue solution for 5 min and the residual Coomassie was removed 
running tap water. The images were captured via ChemiDoc™Touch Imaging System 
(BioRad, USA). Colony number and size were calculated via imagej.  
Western blot 
1 million of cells were seeded in p100 plates and were cultured in the 
corresponding growth medium for 24h before protein extraction. For the Senexin B 
treatment, 0.5 million of cells were seeded in 6-well plates and cultured for 24h and then 
Senexin B or DMSO as control were added into the medium and incubated for another 24 
h, and then the cells were applied for the following protein extraction. Briefly, growth 
media was aspirated and the cells were washed twice in ice cold PBS. Cells were 
subsequently lysed in 0.5 ml 1x RIPA Buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM 
Na2EDTA, 1 mM EGTA, 1% NP-40 1% sodium deoxycholate, 2.5 mM sodium 
pyrophosphate, 1 mM b-glycerophosphate, 1 mM Na3VO4, 1 µg/ml leupeptin) plus Halt 
Protease Inhibitor cocktails (Thermo Scientific). The cell lysates were gathered with a 
plastic cell CytoOne fixed blade scraper (USA Scientific) and transferred into the 1.5 
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Eppendorf tube and kept on ice. The DNA binding proteins were further released by 
ultrasonication shearing on ice. The lysate was centrifugated at 4°C and 14,000 rpm for 
10 min and transferred to a fresh 1.5ml.  
The total protein concentration of the lysate was calculated using the DC™ 
Protein Assay (BioRad, USA). Series dilution of BSA (bovine serum albumin) in RIPA buffer, 
10 mg/ml, 5 mg/ml, 2.5 mg/ml, 1.25 mg/ml and 0 mg/ml, were used as standard protein 
concentration. 5 µl cell lysates were loaded into the wells of 96-well plate (CytoOne Non-
Treated, USA Scientific). 25 µl reagent A with 0.5 µl reagent C was added into the wells 
with sample. 200 µl reagent C was added and mixed thoroughly. After 15 min incubation 
in the dark area at room temperature, the absorbance at 750 nm was measured iMark™ 
Microplate Absorbance Reader. The concentration of cell lysate was calculated by the 
equation gotten from the standard curve. 
10 or 12 % Sodium Dodecyl Sulphate Polyacrylamide (SDS-PAGE) gels made in 
accordance with the recipe from Cold Spring Harbor Protocols.  samples with 50 µg 
protein were mixed thoroughly with loading buffer, with 10 % glycerol, 60 mM Tris/HCl 
pH 6.8, 2 % SDS, 0.01 % bromophenol blue, 1 % beta-mercaptoethanol at final point. The 
mixture was heated in the PCR machine for 10 min at 99°C to denature protein. In the 
first well of the polyacrylamide gel, 7 μl protein marker, Precision Plus Protein™ Dual 
Color Standards (BioRad, USA), was loaded. In the subsequent wells, equal amounts of 
the sample proteins of interest were loaded. Electrophosesis was carried out in 1X 
running buffer (25 mM Tris-HCl, 200 mM glycine, 0.1 % SDS, pH 8.8) at 100V until the 
protein of interest reach the middle of the whole gel as indicated by the protein marker. 
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The fractionated proteins were subsequently transferred onto Immun-Blot® PVDF 
Membrane (BioRad, USA). Briefly, the PVDF membrane was activated by methanol for 1 
min. The transfer cassette was settled up by putting fiber pad, filter paper, FVDF 
membrane, gel, filter paper and fiber pad from positive electrode to negative electrode. 
The cassette was then immersed in transfer buffer (25 mM Tris, 192 mM Glycine, 20% 
(v/v) methanol, pH ~8.3).  100V electricity was applied for 90 min at 4°C.   
The PVDF membrane with transferred proteins was blocked with 1% BSA in TBST 
(200 mM Tris, 1.5 M NaCl, 0.05 % (v/v) Tween 20, pH ~7.4) for 1 hour at room 
temperature. The membrane was subsequently incubated with primary antibody in 1% 
BSA in TBST over night at 1% BSA in TBST. The primary antibodies used were : CDK8 (sc-
1521, SantaCruz, USA), CDK19 (HPA007053, Sigma-Aldrich), SMAD4 (9515s, Cell Signaling 
Technology, Danvers, MA, USA), Phospho-STAT1 (ser727) (8826s, Cell Signaling 
Technology, Danvers, MA, USA), STAT1 (9172s, Cell Signaling Technology, Danvers, MA, 
USA), β-Catenin (9587s, Cell Signaling Technology, Danvers, MA, USA), Timp3 ( ab39184, 
Abcam, USA), GAPDH (#5174, Cell Signaling Technology, Danvers, MA, USA). The 
membrane was washed thoroughly with TBST for 10 min for 3 times and then incubated 
with horseradish peroxidase-conjugated secondary antibody in 1% BSA in TBST for 1 hour 
at room temperature. The secondary antibodies used were: anti-goat (sc-2020, 
SantaCruz), anti-rabbit (#31460, ThermoFisher Scientific) or anti-mouse (31430, 
ThermoFisher Scientific) secondary antibodies. After 3 washing steps with TBST, 10 min 
for each, the membrane was incubated with Western Lightning Plus-ECL (PerkinElmer 
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Inc.) for 5 min. The luminescence was detected via ChemiDoc™Touch Imaging System 
(BioRad, USA). The signal strength was measured via Image Lab 5.2.1 (BioRad, USA). 
RNA extraction, reverse transcription, and q-PCR (Quantitative real-time PCR) 
0.2 million of cells were seeded in 6-well plates and were cultured in the 
corresponding growth medium for 24h before RNA extraction. For the Senexin B 
treatment, 0.1 million of cells were seeded in 6-well plates and cultured for 24h and then 
Senexin B or DMSO as control were added into the medium and incubated for another 24 
h, and then the cells were applied for the following RNA extraction. The RNA extraction 
was performed with RNeasy Mini Kit (Qiagen, Hilden, Germany) and all the reagents was 
prepared following the instructions. Briefly, cell culture media was removed and 350μl 
RLT/ β -ME cell Lysis buffer was added directly to the cells. The plate was rocked a few 
times to let the Lysis buffer cover all the area and left at room temperature for 3~5min to 
ensure complete Lysis. The 350ul lysate was transferred to the QIAshredder spin column 
for homogenization by centrifuged at 13,000 rpm for 2 min. The filtrated lysate was 
mixed with 1 volume (350μl) of 70% ethanol pipetted up-and-down 3~4 times. The 
mixture was then loaded to RNeasy Mini column and centrifuged at 14,000 rpm for 30 
sec. The flow-through was discarded. 700 µl buffer RW1 was loaded to RNeasy Mini 
column and centrifuged at 14,000 rpm for 30 sec.  700 µl buffer RPE was loaded to 
RNeasy Mini column and centrifuged at 14,000 rpm for 30 sec. The column was 
transferred to another new collecting tube and centrifuged at 14,000 rpm for 2 min to 
make sure there was no RPE carryover. The column was carefully transfer to another new 
1.5ml collecting tube and 40µl water (RNase-free) was loaded and incubated at room 
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temperature for 2 min. The RNA was collected by centrifugation at 14,000 rpm for 2 min.  
The RNA concentration was measured with NanoDrop Spectrophotometer (Thermo 
Scientific). RNA purity assessed using the A260/A280 ratio method with a ratio >2 
deemed acceptable. 
1 µg of total RNA was used to generate cDNA using iScript cDNA synthesis kit 
(BioRad, Hercules, CA, USA). Briefly, 1 µg of total RNA at 10 µl was mixed with 5 µl water 
and 2 µl reaction buffer and 1 µl enzyme in the PCR tube. Bio-Rad T100TM Thermal Cycler 
was used to process the RNA to DNA reaction by incubating the reaction mix at 25°C for 5 
min, 45°C for 30 min, 85°C for 5 min and held at 4°C. The 20 µl obtained cDNA was 
diluted with 180 µl nucleotidase free water and ready for the qPCR test. 
qPCR was performed with the machine Bio-Rad CFX384 Touch™ Real-Time PCR 
Detection System. Briefly, 3.3 µl diluted cDNA was mixed with 4.95 µl iTaqTM Universal 
SYBR® Green Supermix and 0.5 µl 10 µM primers (forward and reverse) and 3.95 µl 
nucleotidase free water. The mixed reaction solution was put into the qPCR machine and 
incubated at 95°C 3 min for priming and then followed with incubated at 95°C for 5 
second and 60 °C for 30 second, the late two steps were repeated for 40 cycles. After the 
amplification steps, the sample was incubated at 65 °C and the temperature was 
increased by 0.5°C per second to 95°C to get melting curve for each amplified DNA 
fragment. Ct (threshold cycle), the intersection between an amplification curve and a 
threshold line, was used to determine the template amount in each sample. The qPCR 
data were analyzed by the double delta Ct method. Basically, the average of the Ct values 
for the housekeeping gene and the gene being tested in the experimental and control 
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conditions were used. The 4 values are Gene being Tested Experimental (TE), Gene being 
Tested Control (TC), Housekeeping Gene Experimental (HE), and Housekeeping Gene 
Control (HC). The differences between TE and HE (TE-HE) and TC and HC (TC-HC) were 
the ΔCt values for the experimental (ΔCTE) and control (ΔCTC) conditions, respectively. 
The difference between ΔCTE and ΔCTC (ΔCTE-ΔCTC) was Double Delta Ct Value (ΔΔCt). 
The gene expression fold change was 2^-ΔΔCt. In some case, the gene expression level 
was described as the expression level relative to the certain housekeeping gene and 
calculated as 2^(HE-TE). All the qPCR tests were run in triplicate.  
Primers used for real-time PCR are listed in Supplemental Table 4.2. 
TABLE 4.2 QPCR primer sequences 
mSMAD4-F ACACCAACAAGTAACGATGCC mSMAD4 
mSMAD4-R GCAAAGGTTTCACTTTCCCCA 
 
mCTNNB1-F CGCTGCTCATCCCACTAATGTC mCTNNB1 
mCTNNB1-R TCCGCGTCATCCTGATAGTTAATC 
 
mCDK8-F CGGGTCGAGGACCTGTTTG mCDK8 
mCDK8-R TGCCGACATAGAAATTCCAGTTC 
 
mCDK19-F GGTCAAGCCTGACAGCAAAGT mCDK19 
mCDK19-R TTCCTGGAAGTAAGGGTCCTG 
 
mMMP10-F GAGCCACTAGCCATCCTGG mMMP10 
mMMP10-R CTGAGCAAGATCCATGCTTGG 
 





mMMP3-F TTAAAGACAGGCACTTTTGGCG mMMP3 
mMMP3-R CCCTCGTATAGCCCAGAACT 
 
mRPL13A-F GGGCAGGTTCTGGTATTGGAT mRPL13A 
mRPL13A-R GGCTCGGAAATGGTAGGGG 
 
mSTAT1-1-f GCTGCCTATGATGTCTCGTTT mSTAT1 
mSTAT1-1-r TGCTTTTCCGTATGTTGTGCT 
 
mTIMP3-F CTTCTGCAACTCCGACATCGT mTIMP3 
mTIMP3-R GGGGCATCTTACTGAAGCCTC 
 
RPL13A-F GGCCCAGCAGTACCTGTTTA hRPL13A 
RPL13A-R AGATGGCGGAGGTGCAG 
 
TIMP3-F GGTGAAGCCTCGGTACATCT hTIMP3 
TIMP3-R AGGACGCCTTCTGCAACTC 
 
CDK19-F GTTTCACCGTGCATCAAAAGC hCDK19 
CDK19-R ACCCAATTTGCATGGAGGTAATG 
 
CDK8-F AAGTTGGCCGAGGCACTTAT hCDK8 
CDK8-R ATGCCGACATAGAGATCCCA 
 
MMP2-F AAGAAGTAGCTGTGACCGCC hMMP2 
MMP2-R TTGCTGGAGACAAATTCTGG 
 





MMP7-F GCATCTCCTTGAGTTTGGCT hMMP7 
MMP7-R GAGCTACAGTGGGAACAGGC 
 
MMP9-F ACGACGTCTTCCAGTACCGA hMMP9 
MMP9-R TTGGTCCACCTGGTTCAACT 
 
MMP10-F CTGATGGCCCAGAACTCATT hMMP10 
MMP10-R ACTGGAACCCTGAACCTGAA 
 
MMP13-F CACCAATTCCTGGGAAGTCT hMMP13 
MMP13-R GCAGCTGTTCACTTTGAGGA 
 
mmir-21a TGTACCACCTTGTCGGATAGCTTATC miRNA PCR 
mmir-181a-1 GGTTGCTTCAGTGAACATTCAAC miRNA PCR 
mmir-181a-2 CCATGGAACATTCAACGCTGTCG miRNA PCR 
mmir-181b-1 AGGTCACAATCAACATTCATTGC miRNA PCR 
mmir-181b-2 TTGATGGCTGCACTCAACATTCAT miRNA PCR 
mmir-181c GCCAAGGGTTTGGGGGAACATTC miRNA PCR 
mmir-181d ACAATTAACATTCATTGTTGTCG miRNA PCR 
mmir-21b TTTGAGGATACTCTTGCATATGGA miRNA PCR 
mmir-125b-1 TGCGCTCCCCTCAGTCCCTGAG miRNA PCR 
mmir-125b-2 GCCTAGTCCCTGAGACCCTAAC miRNA PCR 
mmir-712 TCTCCGCTTCTCCTTCACCCGGGC miRNA PCR 
URT AACGAGACGACGACAGACTTTTTTTTTTTTTTT miRNA PCR 




Gene expression modification 
Transforming competent cells 
30 μl One Shot® Stbl3™ Chemically Competent E. coli (ThermoFisher Scientific) 
mixed with about 100 ng plasmids was subjected to heat-shock treatment by incubation 
on ice for 20 minutes followed by incubation at 42°C for 45 seconds and then put on ice 
immediately for a further 2 min. The DNA/bacteria mix was then transferred into 450μl of 
sterile LB broth and incubated at 37°C. After 1 hour, 10 μl and 100 μl of E. coli was 
seeded and spread on pre-warmed LB agar plates (containing 50μg/ml ampicillin from 
Sigma-Aldrich) separately which were then incubated overnight at 37°C. The following 
day, individual bacterial colonies were transferred to separate falcons containing LB 
broth with ampicillin (50μg/ml) and then incubated with shaking in the incubator-shaker 
overnight at 37°C. The following day, bacterial cells were spin down at 3000rpm for 10 
min. 
Plasmid DNA was extracted from the bacterial pellet using the QIAprep® Miniprep 
kit (Qiagen) following the manufacturer’s instructions. DNA was eluted in 50μl of 
nuclease-free water, quantified using a Nanodrop 1000 spectrophotometer (Thermo 
Scientific) and stored at -20°C. 
Plasmid construction 
To construct the plasmid pLenti6-hTIMP3, which is suitable for lentivirus 
transduction, 2 µg pLenti6-TR plasmid (Thermo Fisher Scientific) was digested with 
FastDigest XbaI (Thermo Fisher Scientific) at 37°C for 1 hour. The product was loaded to 
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the 0.8% agarose gel for separation. The bigger fragment was recycled by the QiaQuick 
Gel Extraction Kit (Qiagen) and the was dephosphorylated by Antarctic Phosphatase (New 
England Biolabs®. Inc) and the product was labelled as pLenti6/XbaI/AP. Human TIMP3 
cDNA fragment was amplified from pRK5M-TIMP3 (31715, Addgene) by PCR with the 
primers. The PCR product was digested with FastDigest XbaI (Thermo Fisher Scientific) at 
37°C for 1 hour and then loaded to 0.8% agarose gel for DNA separation. The DNA band 
was recycled with QiaQuick Gel Extraction Kit and labelled as hTIMP3/Xbal. 
pLenti6/XbaI/AP and hTIMP3/Xbal was ligated by CloneDirect™ Rapid Ligation Kit 
(Lucigen). 2uL of ligation was used to do bacteria transformation. The plasmids from the 
clones were checked with Hind III digestion and Clal plus Pst I digestion. The correct 
plasmid was named as pLenti6-TIMP3. 
The shRNAs plasmids that have the highest adjusted scores according to the 
Genetic Perturbation Platform (broad institute) were purchased from Sigma-Aldrich. 
Lentivirus production 
All the procedure of lentivirus production was performed as BIO-HAEZARD II level. 
The pipette or tip used were soaked in 10% bleach for at least half hour before disposed 
to regular orange biohazard bags. The media containing virus was neutralized by 10% 
bleach (at 1:1 ratio) for at least half hour before being aspirated into regular liquid 
disposal. 5 million of 293FT cells were seeded into the PEI (polyethylenimine) 
(SigmaAldich) pre-coated p100 dish. The second day, DNA mixture (0.25 μg pCMV-dR8.91 
and 0.075 μg pCMV-VSV-G and 5 μg lentiviral construct) was transfected into 293FT cells 
112 
 
via Lipofectamine 3000 Reagent (ThermoFisher Scientific). 8 h after transfection, the 
medium was changed. Another two days late, the virus-containing media were collected 
and filtered with 0.22 μm filter. The virus- containing medium was ready for cell 
transduction or being stored at -80°C. 
Lentivirus transduction 
Before the lentivirus transduction, the target cells were challenged by different 
concentration of puromycin (Sigma-Aldrich) or blasticindin (Sigma-Aldrich) from 1 μg/ml 
to 10 μg/ml. the lowest concentration that killed all the cells in one week was used in the 
following selection. The cells were also challenged by different concentration of 
hexadimethrine bromide (Sigma-Aldrich) and the highest concentration that left the cells 
growth normally in 24 h was used in the following experiment.  For the transduction, 0.1 
million of CT26 cells were seeded into 6-well plate. A series of dilution of collection of 
virus- containing medium were applied onto the cells with hexadimethrine bromide to a 
final concentration of 8 µg/ml. 8 h after the transduction of lentivirus, the lentivirus-
containing medium will be collected and lentivirus inactivated by mixing with 10% final 
concentration of bleach for 12 h. The transduced cells will be cultured in normal growth 
medium for 48 h. After that, puromycin will be added into the growth medium at 10 
µg/ml, which was based on our previous puromycin killing curve in CT26 cells. After three 
rounds of puromycin treatment, 3 days for each round, the stable knockdown cells will 
be cultured in puromycin-free medium for one week and then frozen in 20 vials. For the 
overexpression of hTIMP3, the transduced cells were selected with 5 µg/ml blasticindin 
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for three rounds of puromycin treatment, 3 days for each round. The obtained cells were 
checked by qPCR and western blot assays for knockdown or overexpression efficacy. 
Microarray analysis 
Total cellular RNA from different kinds of cells with different treatment was 
extracted as described previously and RNA quality was tested using Bioanalyser (Agilent, 
Santa Clara, CA, USA). Microarray analysis of CT26-plko.1 (CT26 cells shRNA vector 
control) and CT26-shCDK8-1 (CT26 cells with stable CDK8 knockdown by shRNA, number 
1) was performed on Illumina expression microarray platform by Proteogenomics Facility 
at Medical University of South Carolina. Microarray analysis for the comparison between 
CT26 cells treated with DMSO and 5 µM Senexin B for 24 hour and the comparison 
between CT26-plko.1 and CT26-shCDK8-2 (CT26 cells with stable CDK8 knockdown by 
shRNA, number 2) were performed via Affymetrix Mouse gene 2.0 X ST arrays, conducted 
by Microarray Core Facility of College of Pharmacy at the University of South Carolina. 
Microarray data were analyzed using Expression Console (Thermo Fisher Scientific). A 
subset of identified genes was validated in biological triplicates by q-PCR.  
In vivo experiments 
All animal studies were performed according to guidelines established by the 
Institutional Animal Care and Use Committee (IACUC) at the University of South Carolina 
(Columbia, SC). All instruments used were autoclaved and then sterilized by glass bead 
sterilization in between surgeries. The female BALB/cJ mice at 6 to 7 weeks were bought 
from The Jackson Laboratory and the male nude mice at 6 to 7 weeks were purchased 
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from Taconic Biosciences. The animals were kept at the animal facility at the University of 
South Carolina. Animals were free access to the water and food and the cycle of day and 
night was 12 h to 12 h.  
Metastasis model 
The female BALB/cJ mice (nude mice for the HCT116 cells) were anesthetized in 
an induction chamber with 2-5% isoflurane in oxygen administered by inhalation and 
delivered by an EZ anesthesia vaporizer. The depth of anesthesia is monitored by 
observing for the lack of response to a toe pinch and lack of palprebral reflex. The mice 
were then transferred to the surgical table. Anesthesia was maintained in 2% isoflurane 
in oxygen throughout the duration of the surgery using a nose cone. The abdominal area 
above spleen was shaved to remove hair prior to surgery and sterilized with 70% ethanol 
swabs prior to incision. Buprenorphine was admnistered i.p. (0.05-0.1 mg/kg) as pre-
emptive analgesia prior to surgery. A small abdominal incision about 1 cm above the 
spleen was made and the wound margins was covered with sterile gauze moistened with 
phosphate buffered saline (PBS) to prevent peritoneal spread of cells and drying up. The 
spleen was exposed through the incision; 0.2 × 10^5 CT26 cells in 20 μl of DMEM (1 x 
10^6 HCT116 cells in 100 μl of DMEM) were injected into the spleen via a 33-gauge 
needle. Depending on the experiment we will then perform one of the following 
procedures:  
a) For routine metastasis study on the model with CT26 cell injection, the site of injection 
was sealed with Tissue Adhesive (3M Vetbond™) to prevent tumor cell escape and 
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leakage. The spleen was rinsed successively with PBS and 70% ethanol to remove any 
cells that may have potentially leaked out during injection. 
b) For survival experiment on the model with CT26 cells injection and routine metastasis 
study with HCT116 cell injection, the spleen was removed by splenectomy 1 min after the 
injection of tumor cells into the spleen. The artery was tied off with a 4-0 suture (492A 
Suture CP Medical) by looping through the mesentery and the mesentery and connective 
tissue will be cauterized and the spleen removed. 
The abdominal incision was then sutured in two layers by continuous suture with 
a 6-0 absorbable suture (492A Suture CP Medical). After surgery, the mice were given 
500 μl of saline to keep them hydrated. Mice were kept in cages placed on a heating pad 
(maintained at 37°C) for recovery from anesthesia and are ambulatory within 5 - 10 
minutes after the surgery. They were closely monitored for pain and discomfort and for 
proper healing of incision, daily for one week post-surgery. Buprenorphine (0.05-0.1 
mg/kg) was administered i.p. as needed.  
Synograft s.c. model 
The mice were anesthetized in an induction chamber with 2-5% isoflurane in 
oxygen administered by inhalation and delivered by an EZ anesthesia vaporizer. The 
depth of anesthesia is monitored by observing for the lack of response to a toe pinch and 
lack of palprebral reflex. To establish synograft s.c. model, a single-cell suspension of 1.0 
x 10^6 CT26 cells were obtained from 50%-70% confluent adherent cultures and 
suspended in 100 μl of sterile PBS was injected s.c. into the flanks of 7 to 8 weeks old 
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female BALB/cJ mice with a Sub-Q26G5/8 needle. Animals were allowed to recover on 
the warm plate and then returned to cages. Tumor dimensions were measured using 
calipers. To approximate the subcutaneous tumor size, the calipers was compressed on 
the skin slightly but not so tightly as to grip the subcutaneous mass. The maximal 
dimension of the tumor was recorded as L. The dimension crossing the L as W. The 
formula: Volume = L x W x W/2 will be used. The volumes of growing tumors were 
measured twice per week.  
The delivery of Senexin B 
For the s.c. synograft model: When the average tumor volume reached 100 mm3, 
the mice were randomly grouped. Senexin B dimaleate was administered by gavage at 50 
mg/kg doses (weight doses calculated for Senexin B dimaleate rather than free Senexin B) 
in 6.25% 2 Hydroxypropyl β cyclodextrin, 1% Dextrose buffer (CD vehicle), b.i.d. or with 
the vehicle control.  
For the metastasis model: The treatment of this model was started at the first of 
surgery, or as specifically indicated. There were several of methods of the delivery of 
Senexin B were performed. Each of them was: mice were treated by daily i.p. injection of 
Senexin B dichloride (40 mg/kg) in 10 mM citrate buffer, pH6, 150 mM NaCl or with 
vehicle control; Senexin B dimaleate was administered by gavage at 50 mg/kg doses in CD 
vehicle, b.i.d.; mice were treated with the control diet (Research Diets, D12450B) or the 
Senexin B mixed in the diet at the concentration 0.4mg/g as low dosage and 1.4 mg/g as 
high dosage; mice were treated with the combination of low dosage of diet with Senexin 
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B and the Senexin B dimaleate administered by gavage at 50 mg/kg doses in CD vehicle 
daily.  
All animals were observed daily for tumor growth and morbidity, as well as side-
effects such as weight loss, diarrhea, and respiratory distress which may be associated 
with the chemotherapeutic drugs. Animals were sacrificed at the end point of each part 
of the study or if they are moribund, and if the tumors appear to significantly inhibit their 
movement. Tumor burden was not allowed to exceed 10% of body weight or tumor size 
reached around 2000 mm3. Any animal found to be moribund, cachectic, or unable to 
obtain food or water, as well as those in which body weight has decreased by more than 
20% compared with control animals, or more than 20% over a period of 7 days were 
euthanized. Body condition will also be determined as tumor growth may cause body 
weight to stay the same or even increase, but loss of muscle and subcutaneous fat may 
lead to a marked loss of body condition. This will be evaluated through feeling the pelvis 
and backbone, or if evidenced by a square tail due to muscle atrophy revealing the 
square shape of the vertebrae.  
The mice were sacrificed after anesthetization in the induction chamber 5% 
isoflurane in oxygen administered by inhalation and delivered by an EZ anesthesia 
vaporizer for 5 min. Half of the tumors or organs was kept into the 10% neutral buffered 
Formalin (Sigma-Aldrich) overnight. The fixed tissue was processed as putting in 70% 
ethanol for 1 hour, 95% ethanol for 1 hour, 100% ethanol for 1h ,100% ethanol for 
another 1 h, xylene for 1 h, xylene for another 1 h, paraffin wax at 58°C for 1 h, paraffin 
wax at 58°C for another 1 h and then embedded in the paraffin blocks. Tumor fragments 
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or organs measuring 20-30 mg were snap frozen by putting into the liquid nitrogen for 
RNA or protein analysis.  
H&E staining 
The H&E staining was performed by Instumentation Resource Facility at 
University of South Carolina School of Medicine. Briefly, paraffin section containing the 
tissue of interest was cut from the tissue blocks and placed on slide glass and then in the 
slide holder. The slides were then deparaffinized and rehydrate by going through three 
times of xylene for 10 min and three times of 100% ethanol for 1 min, 95% ethanol for 30 
second, 75% ethanol for 30 second and in water for 1 min. After rehydratation, the slides 
were put into the hematoxalin for 3 min and then put into the tap water for 5 min for 
development and destained in acid ethanol (1 ml concentrated HCl + 400 ml 70% 
ethanol) by dipping a few times. After washing with deionized water for 2 min, the slides 
were transferred into eosin solution for 30 seconds and then transferred into 95% 
ethanol and 100% ethanol for dehydration. The slides were then put into xylene for 15 
min and repeat once. A drop of Permount (#SP15 100, Fisher Scientific) was put on the 
stained tissue section and coverslip was used to cover and seal the staining. The H&E 
staining images were acquired with Leica DM1000 LED microscope and Leica Application 
Suite EZ. Tumor area quantification was performed by the software Image-Pro® Plus 6.0 
and analyzed by ImageJ software.  
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Histology and Immunofluorescence (IF) 
For IF staining, sections of tumor tissues (5 μm) were deparaffinized, rehydrated 
as described in H&E staining. Antigen was retrieved by maintained in antigen retrieval 
buffer (10 mM Sodium citrate, 0.05% Tween 20, pH 6.0) at 120 °C for 5 min. Slide was 
blocked in PBS containing 5% goat serum and 0.3% Triton-X-100 for 1 h at room 
temperature. Tissues were then incubated at 4°C overnight with primary antibody in 
TBST with 1% goat serum.  Secondary antibodies conjugated with Alexa Fluor 594 
(targeting mouse) and with Alexa Fluor 488 (targeting rabbit) was used for 1 hour at 
room temperature. After counterstaining in 300 nM DAPI in PBS for 1 min, sections were 
mounted with 80% glycerol in PBS. Images were taken by Olympus IX81 and analyzed 
using ImageJ. 
RNA preparation from tissue 
The sample of tissue or tumor at around 20-30 mg was homogenized in 1000 µl of 
TRIzol® Reagent (Ambion® | Thermo Fisher Scientific) via homogenizer POWERGEN 125 
(Fisher Scientific) and kept at room temperature for 5 min to permit complete 
dissociation of the nucleoprotein complex. 0.2 ml of chloroform was used for 
homogenization by shaking tube vigorously for 15 seconds. The sample was kept at room 
temperature for 3 min and then centrifuged at 12,000 g for 15 min at 4 °C. The aqueous 
phase of the sample was transferred into a new tube and mixed with 0.5 ml of 100% 
isopropanol and then kept at room temperature for 10 min. the RNA pellet was spin 
down by 12,000 g for 10 min at 4 °C and then washed with 75% ethanol for twice. After 
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removal of the ethanol, 500 µl of RNase free water was added to resuspend the RNA 
pellet. The A260/280 ratio of the RNA solution should > 1.9. 
Protein preparation from tissue 
For protein lysate preparation, 2 ml RIPA buffer with Protease Inhibitor cocktails 
(Thermo Fisher Scientific) and 10 mM NaF and 10 mM NaVO3 was applied to 20 mg 
sample. The sample was homogenized via homogenizer POWERGEN 125 (Fisher 
Scientific). The debris was spin down by centrifugation at 14,000 g for 15 min at 4 °C. The 
solution was transferred into a new tube and ready for western blot. 
Statistical analysis 
Most data were presented as mean ± standard error of the mean (SEM) of 
biological replicates.  Meta-analysis of clinical data was conducted using SurvExpress 
(http://bioinformatica.mty.itesm.mx:8080/Biomatec/SurvivaX.jsp). Survival data were 
analyzed by Kaplan Meier survival curves and the comparisons were performed through 
Log Rank test using GraphPad Prism 5 software.  Statistical significance was tested using 
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